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 1 
Preface 
 
The Neurodegenerative process 
 
The term neurodegeneration defines a variety of conditions that modify 
neuron’s normal functions in the human brain in which is possible to observe 
a progressive and consistent neuronal loss. Neurons are cells that form the 
central nervous system (CNS) and they are characterized by inability to 
reproduce or replace themselves. In this way, when damage threatens, the 
loss of cells will be permanent. The definition of neurodegenerative disease 
includes a multitude of diseases which could be separated into two main 
groups, chronic and acute pathologies (1). 
The mechanisms involved in the evolution of these superclass are not 
completely understood yet, however they share common characteristics 
such as misfolded proteins, oxidative stress, inflammation, excitotoxicity and, 
obviously, neuronal loss (2). 
Neurodegenerative chronic diseases are estimated to surpass cancer 
as the most important cause of death by the 2040s (3). This definition 
identifies a variety of pathologies such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease, amyotrophic lateral 
sclerosis (ALS) and so forth, which share many common characteristics like 
oxidative stress, microglia dysfunction and progressive neuronal loss (4). An 
extensive variety of these pathological conditions are characterized by 
proteins accumulation like intracellular or extracellular aggregates (5). This 
process can occur both in sporadic and familial cases, that highlights this 
pathological mechanism strongly correlated with neuron dysfunctions (6). 
Usually, patients are affected later in life, for this reason, in the last 20 years 
the number of diagnosis is prominently enhanced, especially for the increase 
in life expectancy. However, numerous evidences suggest the presence of a 
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preclinical asymptomatic stage that could begin years before the 
establishment of the first symptoms. This stage could be the most important 
phase because represents the time point where is possible to modulate the 
establishment of the disease (7). Patients could present a variety of 
symptoms that frequently occurs when the pathology in CNS is already 
advanced. The current therapy could not restore the physiological central 
condition, but could only operate on the modulation of somatic symptoms 
and, in the best situations, try to slow down the progression of the 
neurodegenerative process without arresting it (8). 
On the other hand, the term acute neurodegeneration describes clinical 
conditions in which neurons are rapidly damaged and usually die in 
response to an insult. This description comprehends stroke, head injury, 
cerebral or subarachnoid hemorrhage, and ischemic brain damage derived 
from fetal or perinatal hypoxia. These conditions cause massive morbidity 
and mortality, and pose an enormous socio-economic burden. Although the 
type of insult and onset of neuronal injury is acute, subsequent neuronal loss 
can occurs hours or days after the initial event. This delayed cell damage 
results from endogenous factors that are released in response to the primary 
injury, which might be common to the clinical conditions outlined. 
Inflammatory processes have been implicated in both acute and 
chronic neurodegenerative conditions (9). The CNS differs in its 
inflammatory response to other tissues. In general terms, cellular infiltration 
in the brain in response to inflammation, infection and injury is weaker and 
delayed, but many inflammatory responses can be induced rapidly (10). 
These include the activation of microglia, and the expression and release of 
classical inflammatory mediators, such as acute-phase proteins, 
eicosanoids, complement and cytokines (11). 
Many studies have shown the frequency to develop a 
neurodegenerative chronic disease several years after an acute brain injury 
(12). In addition, many patients show, after a traumatic brain injury, motor 
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and cognitive manifestations that are close to which are observed in 
neurodegenerative chronic patients. For this reason, in preclinical research, 
it is frequently used a battery of behavioral tests similar to those employed in 
PD or AD studies. These considerations are combined to the fact that 
neuronal death can be caused by protein misfolding, neuroinflammation and 
oxidative stress; these mechanisms are shared by these two different 
superclasses of neurodegenerative diseases. Moreover, it is possible that a 
neuroprotective strategy may be aimed to arrest or slow down the damage 
evolution in both chronic and acute neurodegeneration should act in the 
window of time between the lesion occurred and the propagation of the 
irreversible injury.  
In this context it is evident the importance of understanding how it is 
possible to modulate all these mechanisms and to work on the connection 
between them from the moment that they share a common base. For this 
reason it is evident how is fundamental the concept of neuroprotection as a 
way to modulate and control the evolution of neurodegenerative processes. 
Neuroinflammation, oxidative stress and the apoptotic process may be a 
functional targets where operate to this end. 
Taking into account these considerations, the aim of the present study 
is to identify potential common pathogenetic pathways in neurodegenerative 
diseases using an integrated approach of preclinical studies. The goal is to 
delineate therapeutic strategies for the prevention or reduction of 
neuroinflammation, neurodegeneration and cognitive dysfunction associated 
to PD and cerebral ischemia. The results may contribute to the development 
of pharmacological strategies designed to prevent and counteract 
neurodegenerative damage at morphological functional, biochemical and 
cognitive levels. 
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 PART I 
 
1. INTRODUCTION 
1.1. PARKINSON’S DISEASE 
In 1817 James Parkinson described, in his monograph “Essay in the 
Shaking Palsy”, the essence of the second most common age-related 
neurodegenerative disorder after AD, afflicting approximately 6 million 
people worldwide (2). Parkinson’s disease is a multisystemic slowly 
progressive disorder characterized by a combination of motor and non-motor 
symptoms. The main pathological change in the parkinsonian brain is the 
degeneration of dopaminergic neurons of the substantia nigra pars 
compacta (SNpc) in the ventral midbrain and depletion of dopamine in the 
striatum (STR), principal site where these nerve terminals project. 
Furthemore the condition is associated with an accumulation of neuronal 
inclusions known as Lewy bodies (LBs) (13) (Fig. 1). 
 
Figure 1. Brain Regions involved in Parkinson’s disease. 
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PD is characterized by cardinal motor symptoms, including 
bradykinesia, rigidity, postural instability, and resting tremor. In addition to 
motor symptoms, PD patients also show, during the early stage, non-motor 
manifestations such as autonomic dysfunctions, cognitive abnormalities, 
sleep and mood disorders, pain, and sensory conditions (14). The 
complexity of the pathology makes many difficulties to find the cause of the 
disease and to recognize which is the moment when it starts. This is 
because of the long period between the initiation of the disease and the 
manifestation of clinical symptoms; not less important is the lack of any 
distinctive blood biomarker with which to trace the disease process. 
Moreover, clinical symptoms appear when almost 50% of pigmented 
dopaminergic neurons are dead. In this condition, surviving cells could 
supply the striatum demand only about 20-30% and first motor symptoms 
start to be evident (15). This combination of numerous motor and non-motor 
symptoms makes PD as a unique chronic condition with a lot of questions 
still unanswered. Motor disabilities could restrict patient’s activity and the 
association with non-motor symptoms could importantly worsen their quality 
of life (16). 
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1.1.1. INCIDENCE AND EPIDEMIOLOGY 
PD is a progressive disease with a mean age at onset of 55, the 
pathology’s prevalence rises to 1% in persons 65 years of age, this 
percentage arrives to 3% in individuals with an age over 85 without 
significant difference by the sex (17). In about 95% of cases PD is idiopathic 
multifactorial disease due to environmental factors and genetic susceptibility, 
there is no apparent familiar genetic connection; these cases are referred as 
“sporadic” PD. On the other hand, leftover 5% cases are the result of genetic 
mutations and are inherited (2). Usually the pathology is diagnosed around 
60 years of age, but in 10% of cases the onset would be really earlier around 
45 years, this is considered by the scientific community like precocious 
incidence (18). 
The prevalence and the incidence of PD increase with age, the 
extension of the life expectancy joined with the demographic shift in the 
population could explain the increasing number of cases observed 
worldwide. On the other hand, in the last two decades it was possible to 
observe a progressive increase in the mean age at onset of the disease and 
this aspect is not fully explained by population ageing, but suggest that 
probably additional variables may play a crucial role. Reasonably, the 
increasing awareness of the neurodegenerative chronic diseases, the 
improvement in the time and accuracy of diagnosis could be related with 
these cases. In fact early physical symptoms that in the past were related 
with ageing or missed by older patients now are more referred to the medical 
corps (19). This situation could also be explained by a reduction of cases at 
precocious incidence. The last twenty years have seen significant 
improvements in the medical management of risks factors of PD and, at the 
same time, the increasing consume of non-steroidal anti-inflammatory drugs 
may have contributed to attenuate the pathophysiologic role of 
neuroinflammation (20, 21). Despite the importance that pesticide and other 
toxic-compounds have on the precocious onset of the pathology, at our 
Part I                                                                                                               Introduction 
 
  
 7 
days, thanks the progress and the attention also in this aspect of modern 
life, there is not a significant difference in the incidence of PD in people living 
in rural environment than people living in towns (22). 
The etiology of PD remains to be fully understood, but the most 
plausible theories propose an environmental or genetic origin, or most 
probably a combination of both (23, 24). 
Numerous processes are involved in the onset of the pathology like 
oxidative stress, mitochondrial dysfunction, inflammation, excitotoxicity and 
protein aggregation. In PD, α-synuclein protein (α-syn), the principal 
component of LBs inclusions, plays a key role in the pathogenesis of this 
disorder. The exact biological function of the protein and the mechanism by 
which mutations in this gene lead to neurons loss are still not clear, although 
it has been observed that an excess of α-syn depositions can cause 
dopaminergic neurons loss (25). On the other hand, oxidative damage 
induced by reactive oxygen species (ROS) participates in the progression of 
dopaminergic neurons degeneration. In particular, the metabolism of 
dopamine (DA) might be responsible for the high basal levels of oxidative 
stress in the SN; indeed, dopamine oxidation leads to the formation of 
neurotoxic species (26).  
Currently therapy for PD is the administration of L-Dopamine (L-DOPA), 
a precursor of DA; but with the progression of the disease is necessary a 
higher dose to supply the endogenous deficiency of the neurotransmitter. 
Unfortunately this treatment is only palliative and symptomatic as it could not 
arrest the progression of the disease, but it can only supply the lack of DA. 
In the beginning of the therapy the drug administration presents good results 
because motor symptoms can be well managed, but with the massive loss of 
dopaminergic neurons also the pharmacological treatment loses its efficacy 
(27). Last but not least L-DOPA presents several side effects such as 
dyskinesia and motor fluctuation due to the variation of DA in CNS. This 
mechanism could act a dramatic plasticity’s reduction of dopaminergic 
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structures involving most of STR (28). Before that a symptomatic treatment 
was available, the progression of motor symptoms leads up to death in ten 
years from diagnosis. However expectancy of life strictly depends from the 
age of patients when the pathology arises. 
1.1.2. TIPICAL NEUROPATOLOGY OUTCOME 
PD is a multisystemic disease characterized by a slow progressive 
degeneration of dopaminergic neurons. The pathology presents different 
motor and non-motor symptoms. Usually the pathology is identified when 
first motor symptoms appear. Because of the compensative mechanisms of 
dopaminergic system, motor symptoms appear when more than 50% of 
dopaminergic neurons localized in SN are lost.  
Four cardinal motor symptoms are the central features of PD: resting 
tremors, bradykinesia, rigidity and postural instability. Usually in the first 
appearance of these manifestations, it is possible to notice a side preference 
for the dominant one and gradually spread to the contralateral side, although 
the first side involved tends to remain the most severely affected. In this way 
many patients describe in the beginning micrographia, such as abnormally 
small and cramped, and other impairment in normal life task like fastening 
buttons. Specifically the four cardinal motor symptoms are those described 
below. 
• Resting Tremor 
Tremor may be the most visible sign of PD but rarely is the major cause 
of disability. This is a common initial symptom in 70-90% of patients is 
asymmetric rest tremor especially in younger one. This condition usually is 
distal and involves hands, such as thumb and the wrist with a “pill-rolling” 
movement. Resting tremor may also has a postural component and could 
show a leg tremor at rest (29). 
• Bradykinesia 
This symptom is the most disabling features of the disease and is 
reported from the 80-90% of patients. It consists in slowness in movement 
Part I                                                                                                               Introduction 
 
  
 9 
and it contributes to the inability to arise from a chair, turn in the bed or get 
out of a car. Akinesia is the extreme manifestation of bradykinesia, and is 
define as the incapacity to start a movement (18). From this point of view 
appears clearly why this symptom compromises so deeply the patient’s 
quality of life. 
• Rigidity 
90% of patients present this symptom that consists in resistance to the 
passive movement occurring both in flexor and extensor muscles during the 
entire range of motion. Usually it involves the distal part of limbs and could 
be continuous or intermittent.  
• Postural Instability 
Postural instability is a sign of more advanced PD, and also one of the 
most disabling motor features because predisposes to falls and 
consequently to injures. This symptom, although initially is responsive to 
treatment, often becomes resistant in short time (29). Probably this is 
because of the dramatic decrease of the number of dopaminergic neurons in 
the late stage of the pathology.  
Epidemiologic and clinical data suggest that a wide variety of additional 
features (non-motor symptoms) may precede the traditional motor 
manifestation of PD by long periods (30). Current therapies act mainly on the 
dopaminergic system with the goal to improving motor symptoms. However, 
intrinsic non-motor symptoms of PD are increasingly recognized as being 
critical to identify and treat because of their impact on quality of life in PD, 
perhaps having an even greater impact than motor symptoms. Despite 
increasing evidence of them importance on the quality of life, studies have 
shown that there are several difficult in treatment of these issues (31). 
Although physicians may be aware that this features are common in PD, 
these gaps in treatment may be attributable the necessity for increased 
information about them, and clinical approaches for their assessment and 
management in the context of PD as a whole. The most common non-motor 
symptoms described are autonomic dysfunction, cognitive abnormalities, 
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sleep and mood disorders, pain and sensory disorders. In addition to them 
there are others that are secondary to pharmacotherapy treatment such as 
impulse control disorders and psychosis (32). Because PD is primarily 
recognized as a movement disorder, the natural focus on motor symptoms 
often leads to undervalue non motor symptoms by patients and clinicians. 
The importance of recognizing these features is highlighted by the 
expanding evidence that they cause significant morbidity for patients with 
PD, perhaps equal to the morbidity caused by the motor symptoms, and this 
is particularly true in patients with advanced disease (33). 
1.1.3. ORIGIN AND RISK FACTORS 
PD is a multifactorial and multisystemic progressive neurodegenerative 
disorder. The cardinal features of the disease are a result of the 
degeneration of the dopaminergic nigro-striatal pathway originating in the 
SNpc which terminals projects to STR.  SNpc and STR, which is constituted 
by putamen and corpus caudate, are part of a complex neuronal system that 
include cortex, basal ganglia and thalamus that are responsible of the 
normal motor functions. While neurons of this region are preferentially lost in 
PD, they are not the only ones involved in the progression of the disease. 
Degeneration in other areas could contribute in many of the non-motor 
symptoms of PD, such as depression, dementia, and autonomic dysfunction 
(34). In addition to neuronal loss, surviving neurons contain LBs, which are 
cytoplasmic, eosinophilic inclusions always present in PD and predominantly 
composed by a protein called α-syn (2). Because of the natural ageing of the 
brain, is usual to find LBs inclusions in the brain of people that are not 
diagnosed with PD. It has been suggested that LBs as an incidental finding, 
are a feature of normal ageing without any additional nigral cell loss (34). In 
this way it is possible to conclude that the formation of LBs plays an 
important role in the progression of the pathology, however the 
compensatory mechanisms responsible of their elimination play a more 
important part. At the same time is important to underlie that these inclusions 
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are present in both, sporadic and familial, forms of PD (25). Current 
treatments address the dopaminergic deficit, providing symptomatic benefit 
to many of the motor deficits. However, there are many symptoms that do 
not respond to dopaminergic therapy. In addition, there are no proven 
interventions to slow down the underlying degenerative process. The search 
for such neuroprotective treatments is a critical goal of PD research. In order 
to find neuroprotective strategies, a clear understanding of the mechanism of 
neuron death in PD is needed. Early pathways are not directly linked to the 
execution of cell death. In contrast, distal effectors are intimately involved in 
the death process, and their recruitment directly regulates the likelihood of 
cell death (35) (Fig. 2). 
Most PD cases are of sporadic origin, but about 15% are associated 
with genetic causes. From the various loci associated with PD, named 
PARKs, six proteins have been identified so far. They are linked to either 
autosomal dominant (α-synuclein, UCHL1, and LRRK2/dardarin) or 
autosomal recessive transmission (parkin, DJ-1, and PINK-1), that is more 
severe and characterized by an early onset (35). Among the proteins 
responsible for the familial forms of PD, α-syn has received particular 
attention, not only because it was the first gene product implicated in familial 
forms of the disease but also because it is the major fibrillar protein of the 
LBs. Even if its function is far from being completely elucidated, this protein 
seems to play a major role in cell death processes (36). 
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Figure 2. Cascade of events leads to dopaminergic cell death in PD. Various pathogenetic 
factors interconnect with each other in dynamic network that underlie PD pathogenesis. 
PD pathogenesis is a complex and multifactorial process in which both 
genetic features and environmental stressors converge and compromise 
neuron viability by affecting the cellular systems dedicated to the 
maintenance of homeostasis: protein quality control systems and 
mitochondria (37). 
 Three major dysfunctions are observed in PD, oxidative stress, 
mitochondrial dysfunction and excitotoxicity, all of them associated with cell 
death. Also neuroinflammation plays a crucial role in the evolution of the 
disease. In fact markers, such as activated microglia and increased levels of 
circulating proinflammatory cytokines have been observed in patients’ 
brains. Despite the fact that inflammatory process could contribute to 
neurons lost, the link between anti-inflammatory drugs and PD in humans 
remains uncertain. Some studies have shown how nonsteroidal anti-
inflammatory drugs (NSAIDs) exerting neuroprotective effects in PD animal 
models (38). 
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Oxidative damage and mitochondrial dysfunction contribute to the 
cascade of events leading to the degeneration of dopaminergic neurons. 
Others neurodegenerative diseases are associated with oxidative stress, 
suggesting that this mechanism would be a common way to contribute to 
neuronal damage. Oxidative stress defines disequilibrium between the levels 
of ROS produced and the ability of biological systems to detoxify the reactive 
intermediates. All organisms have developed adaptive responses to 
oxidative stress that result in an increased production of defensive enzymes, 
molecular chaperones and antioxidant molecules (39). ROS can be 
generated through several pathways such as direct interactions between 
redox-active metals and oxygen species, reactions, or by indirect pathways 
involving the activation of enzymes like nitric oxide synthase (NOS) or 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (40). 
Superoxide anion radical (O22-), hydroxyl radical (•OH) and hydrogen 
peroxide (H2O2) are examples of ROS. O22- is produced predominantly by 
mitochondrial complex I and III of the electron transport chain (ETC) and is 
highly reactive. It can cross the inner mitochondrial membrane where it can 
be reduced to H2O2. It can also be generated in peroxisomes which contain 
catalase that allow H2O2 to be converted in water, preventing its 
accumulation. However when peroxisomes are damaged, peroxide is 
released to the cytosol where it contributes to oxidative stress (41). The 
extensive production of ROS in the brain may provide an explanation for the 
magnitude of the role that these reactive molecules play in PD. The brain 
consumes about 20% of the oxygen supply of the body, and a significant 
portion of that oxygen is converted to ROS (42). Numerous evidences 
suggest that a significant contributor to dopaminergic neuronal loss in PD 
brain are ROS, which result from dopamine metabolism, but also low 
glutathione (GSH) levels, and high levels of iron and calcium in the SNpc 
(43). Additionally, the brain contains high concentrations of polyunsaturated 
fatty acids, which under oxidative stress conditions; result in lipid 
peroxidation and the generation of toxic products. 
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GSH is a tripeptide consisting of glutamate, cysteine and glycine, with 
the reactive thiol group of its cysteine residue serving as an effective 
antioxidant. The peptide is synthesized in the cytoplasm but has to be 
transported to the mitochondria, where it functions as an antioxidant 
molecule (44). GSH, with the help of enzymes glutathione peroxidase (GPx) 
and reductase (GR), forms detoxification machinery against these oxidative 
species. GSH levels are finely regulated in healthy neurons, and alterations 
from the physiological basal levels can induce cell death. The depletion 
during PD precedes mitochondrial damage and DA loss and the degree of 
its loss has been observed to correlate with disease severity (45) (Fig. 3). 
 
Figure 3. Oxidative stress and Apoptosis. Chemically reactive molecules containing oxygen 
are produced mainly in mitochondria as a consequence of the basal metabolic activity. 
Oxidatively damaged mitochondria and mutated mtDNA-encoded defective protein subunits will 
impair ECT, which results in less ATP production and more ROS outbreak. Increased ROS 
production promotes accumulation of mitochondrial Ca2+, mitochondrial fragmentation, mtDNA 
damage, disruption of mitochondrial membrane potential, and release of cytocrome C (Cyt C). 
Mitochondrial function imbalance elicits a vicious cycle of ROS damage that ultimately triggers 
apoptosis. 
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During PD, there is a selective inhibition of mitochondrial complex I (CI) 
resulting in mitochondrial dysfunction (46). PD toxins such as 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone act on dopaminergic 
neurons via selective CI inhibition. This complex is considered to be one of 
the most severely affected, in CTE, by age related oxidative stress, resulting 
in mitochondrial dysfunction (47) (Fig.4).  
   
Figure 4. Oxidative phosphorylation and the mitochondrial electron transport chain. A: 
Oxidative phosphorylation: the membrane topology of mitochondrial complexes, the sites of 
proton translocation and the targets of agents that affect the transmembrane proton gradient. B: 
The mitochondrial electron transport chain: the sites of ROS generation and the sites of action 
of commonly used respiratory inhibitors. 
It is therefore evident that neurodegeneration in PD involves an 
interaction between GSH depletion, oxidative/nitrosative stress, 
mitochondrial dysfunction, proteasome inhibition and protein aggregation. 
But the precise relationship among these pathways has not been completely 
defined. Because PD pathology simultaneously involves more than one 
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process, it would be interesting to evaluate the synergistic effect of 
simultaneously occurring processes. It is also possible that the presence of 
mutated α-syn protein or proteasome inhibition may impact on mitochondrial 
function and in combination result in alterations in GSH metabolism and by 
enhanced mitochondrial dysfunction in PD (48). 
Another important mechanism involved in the pathogenesis of PD is 
excitoxicity, a pathological process through which neurons are damaged and 
killed after excessive stimulation of glutamatergic receptors by glutamate, 
the main excitatory neurotransmitter in the CNS. This phenomenon is 
involved in several pathological conditions affecting the CNS such as stroke, 
epilepsy and AD. Excitotoxicity is due to intracellular processes, such as 
calcium overload and bioenergetics changes, which increase the oxidative 
burden and activate apoptosis. Within the basal ganglia other 
neurotransmitter systems, such as GABAergic, cholinergic and 
glutamatergic, are present together with the dopaminergic system. In PD, 
the altered neurotransmission observed within the basal ganglia affects the 
glutamatergic system, thereby suggesting a critical involvement of 
glutamate-mediated excitotoxicity in the pathogenesis as well as in the 
progression of the neurodegenerative process. Glutamate-mediated 
excitotoxicity may be involved in a lethal vicious cycle, which critically 
contributes to the exacerbation of nigrostriatal degeneration in PD (38). 
Not less important is neuroinflammation that has been identified in 
postmortem brain in the form of activated microglia pro-inflammatory 
cytokines in SN and STR and has been suggested as part of the 
pathophysiology of the disease (49). This inflammatory reaction is triggered 
by the presence of LBs beacuse α-syn protein is an activator of microglia. 
The magnitude of activation is dependent on the amount of the α-syn 
present. This can lead to the differentiation of microglia into different 
phenotypes, including antigen presenting or macrophage like forms. The first 
one correlates with lower levels of α-syn, also triggers activation of the 
adaptive immune system through CD4+ T-cells (50). Although higher levels 
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of α-syn are associated with a macrophage-like phenotype, this may not 
apply to all variations of α-syn protein, as specific mutations within the 
protein can trigger a pro-inflammatory phenotype, as opposed to a 
macrophagic one (51). Subsequent exacerbation can follow episodes of 
peripheral infection or a chronic inflammatory condition, causing 
neurotoxicity and the release of nitric oxide (NO) or ROS (52). 
Finally is important to understand the role of environmental toxins in the 
disease’s pathogenesis. Toxins could be inhibitors of CI, they could trigger 
the dopaminergic neurons death, or they could modify the normal 
mitochondrial physiology. Neurotoxins are frequently used to induce 
experimental models of PD in vitro or in vivo. Following three examples: 
 MPTP, is a high lipophilic molecule able to pass the blood brain 
barrier (BBB). MPTP is oxidized by monoammine oxidase B (MAO-B) 
in its active metabolite, the toxin MPP+. This metabolite is much more 
polar so it couldn’t enter in neuronal cell but it need membrane 
transporter for dopamine (DAT). In this way MPP+ is selectively 
concentered in dopaminergic neurons. In the cell the active metabolite 
is found preferentially in mitochondria where is able to interact with 
proteins of CI. 
 ROTENONE is a common pesticide, inhibitor of CI. It is a lipophilic 
molecule so is able to pass BBB and is not selective for dopaminergic 
neurons. Rotenone promotes α-syn aggregation and LBs deposition 
(53). 
 PARAQUAT a powerful weed killer able to induce inhibition of 
complex I and III and to promote α-syn aggregation. This molecule is 
not able to pass the BBB but its structure is very close to active 
metabolite of MPTP, the MPP+, so is able to use the same membrane 
transporter (54). 
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1.1.4. CELL DEATH MECHANISMS IN PD 
Cells respond to stress in different ways, they can activate pathways 
that promote survival or induce programmed cell death to eliminate 
damaged cells. The initial response to a stressful stimulus is regulated 
towards helping the cell to defend against it and recovering from the insult. 
However, if the noxious stimulus is unresolved, cells activate death signaling 
pathways. Survival critically depends on the ability to give an appropriate 
response towards environmental or intracellular stress stimuli. The adaptive 
capacity of a cell definitely determines its fate. Therefore, depending on the 
level and mode of stress, different defense mechanisms and pro-survival 
strategies are mounted; however, if these are unsuccessful, then the cell 
death programs are activated to eliminate these damaged cells from the 
organism. The mechanism, by which a cell dies, that is, apoptosis, necrosis, 
or autophagic cell death, often depends on its ability to survive in those 
conditions (55). 
Differently from other cells, neurons have a long life because of them 
role in the neuronal system. Initially it is possible to see an overproduction of 
neurons, this condition is important because allows the system to reach the 
correct number of cells to build complicated neuronal circuits. After an injury 
that would be caused by a disease, or ageing or a trauma condition, neurons 
die, never be substitute and neuronal connectivity is lost. 
Programmed cell death, apoptosis, is a physiological process that 
occurs naturally during life in which intrinsic molecular programs are 
activated to cause cell death. Inappropriate apoptosis control is implicated in 
many human diseases including neurodegenerative disorders: in these 
cases the apoptotic rate is increased and the consequent tissue damage 
may be evident. On the contrary, when apoptosis is reduced, cells that 
should be eliminated may persist and reproduce, like in tumors. Apoptosis is 
considered as the dominant mechanism for neurodegeneration in PD (56). It 
takes place rapidly and is characterized by a series of distinct morphological 
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and biochemical alterations such as condensation and fragmentation of 
nuclear chromatin, condensation of cytoplasmic organelles, and dilatation of 
the endoplasmic reticulum (ER) (57). There are two main apoptotic 
pathways, extrinsic and intrinsic. Although each pathway employs a different 
set of initiator caspases, both share the same executioner caspases. 
Caspases family includes 14 aspartic acid-specific cysteine proteases 
involved either in inflammation or apoptosis. They are synthesized as 
inactive zymogens called procaspases that require cleavage and 
dimerization for activation. Executioner caspases are responsible for most of 
the morphological and biochemical transformations observed in apoptotic 
cells. In the case of the extrinsic pathway, apoptosis is triggered by 
activation of 
death receptor, members of the Tumor Necrosis Factor receptor (TNFR) 
family by their ligands, event that leads to the recruitment of procaspase-8 
(58). 
The intrinsic pathway is also known as mitochondrial pathway 
depending on the release of apoptotic factors from mitochondria (59). This 
pathway may play a major role in triggering apoptosis in PD (58). The 
intrinsic pathway is activated by cellular stresses like growth factor 
deprivation, cytoskeletal disruption, DNA damage, ROS production, and 
accumulation of unfolded proteins. All these changes influence the inner 
mitochondrial membrane with the opening of the mitochondrial permeability 
pores, loss of the mitochondrial transmembrane potential, and release of 
pro-apoptotic proteins from the intermembrane space into the cytosol. The 
central phenomenon in this pathway is the release by mitochondria of 
cytochrome C (cyt C) which induces polymerization of cytosolic Apaf-1, 
adaptor protein of the intrinsic pathway that it is required for activation 
caspase-9 (60). This complex then binds procaspase-9 to activate it in the 
active form caspase-9, which, together with Apaf-1 forms the apoptosome 
complex. Finally, the apoptosome complex plays a role in activation of 
caspase-3 (58).  This mechanism is highly regulated by proteins of the Bcl-2 
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family, comprising members that have either anti-apoptosis (such as Bcl-2 
and Bcl-xL) or pro-apoptosis (such as Bax and Bak) effects (61). Structurally, 
all these proteins share some degree of similarity and can have up to four 
Bcl-2-homology domains (BH1 and BH4). In addition to the Bcl-2 members 
that contain multiple BH domains, there are molecules that share sequence 
homology only with the BH3 domain, which induce cell death by playing a 
crucial role in activating Bax, either by directly facilitating Bax oligomerization 
and translocation to the mitochondria or by inactivating anti-apoptosis 
proteins (62).  
Crosstalk between the extrinsic and intrinsic pathways occurs through 
caspase-8-mediated cleavage of the domain of Bcl-2 protein that interacts 
with death agonist. This is able to translocate to mitochondria where it can 
cooperate with pro-apoptotic Bax and Bak in determining the 
permeabilization of the mitochondrial membrane (62). The changes of 
mitochondrial membrane integrity result in the decrease of the mitochondrial 
transmembrane potential and in the release of several pro-apoptotic proteins 
(63). This release in turn causes disturbances of mitochondrial 
transmembrane potential and the alteration of cell’s biochemical 
homeostasis since ATP synthesis is prevented while NADH, NADPH, and 
glutathione are oxidized and ROS excess is produced (64).  
The extrinsic and intrinsic pathways both activate the executioner 
caspases that modulate the beginning of the “execution phase” of apoptosis. 
Caspase-3, -6, and -7 function as apoptotic effectors, cleaving different 
cellular substrates and activating cytoplasmic endonucleases and proteases 
that degrade the nuclear material and cytoskeletal proteins respectively (65) 
(Fig 5). 
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Figure 5. Extrinsic and intrinsic apoptotic pathways. The extrinsic pathway is activated by 
death receptor activation. The intrinsic pathway is activated by cellular stresses which result in 
the perturbation of mitochondria and the release of pro-apoptotic factors such as cyt C that, 
once released, binds the adapter protein Apaf1 to form the apoptosome complex leading to the 
activation of caspase-9 and the downstream elements of the caspase cascade. Crosstalk 
between the two pathways occurs through caspase 8-mediated cleavage of the Bcl-2 protein 
Bid.  
Cell homeostasis is disrupted by intracellular accumulation of aberrant 
proteins, inactive enzymes and damaged organelles. Cell response involves 
primarily two major systems for whole protein degradation: the proteasome 
system and autophagy, the latter one has the ability to degrade entire 
organelles. 
Proteasome inhibition is another key event affecting neuronal death in 
PD. The tumor suppressor gene p53 is a sequence-specific transcription 
factor that increases dramatically in response to a variety of cellular stresses 
such as DNA damage or oxidative stress. The p53 is activated by multiple 
post-translational modifications with subsequent stabilization. Once it is 
stabilized, p53 enters the nucleus and regulates the transcription of several 
genes that promote cell death (66). The p53 is also known to be able to 
cause cell death by directly inducing mitochondrial permeability and 
apoptosis, independently of the transcriptional up-regulation of pro-apoptotic 
genes and may interact with numerous Bcl-2 family members (35). The 
regulation of p53 levels in the cell is complex and not completely 
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understood. However, the ubiquitin proteasome system is known to play an 
important role in maintaining low levels of p53 in the cell (67). Accordingly, 
proteasomal dysfunction in PD could lead to increase levels of p53 that 
contributes to the degeneration of dopaminergic cells (Fig. 6). Dopaminergic 
cell death is accompanied by a non-transcriptional increase in 
phosphorylated and then activated p53, and p53 inhibition prevents cell 
death in these models. Phosphorylated p53 accumulates in the SN of mice 
treated with proteasome inhibitor as well as in patients with sporadic PD. 
These data suggest that p53 signaling plays a key role in cell death 
associated with proteasome inhibition and possibly in PD itself. During PD, 
SN neurons accumulate proteins, leading to formation of intraneuronal 
deposits, LBs (68). α-syn, the major component of LBs, is a presynaptic 
protein with a probable role in synaptic function. Under normal physiological 
conditions α-syn is lipid associated but tends to aggregate in the lipid free-
state into higher molecular weight oligomers (69). Formation of these 
aggregates has been directly linked to neurodegeneration in PD. 
 Glutamate receptors over-activation is another important apoptotic 
stimulus for neurons. Accumulation of extracellular glutamate and increased 
stimulation of glutamatergic neurons spreads ROS production inducing 
oxidative stress. Stimulation of these receptors involves calcium 
homeostasis dysfunction, caspases activation, increase in cytotoxic 
transcription factors and free radicals. Excitotoxicity may occur in acute 
neurodegenerative conditions as well as in neurodegenerative chronic 
diseases (60). 
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Figure 6. Mitochondrial functions in the regulation of apoptosis. A major key point in the 
regulation of apoptosis is the ratio of pro-apoptotic to anti-apoptotic Bcl-2 family members. 
Upon receiving an activating signal, the pro-apoptotic members directly engage and activate 
the pro-apoptotic effectors Bax and Bak making them homodimerize and causing their 
translocation to the outer mitochondrial membrane (OMM). Pro-survival Bcl-2 proteins 
constitute a checkpoint for Bak/Bax homodimerization and in turn they can be repressed by 
sensor Bcl-2 proteins. Once inserted into the OMM, Bax/Bak homo-oligomers lead to pores 
formation and MOMP causing the release of several pro-apoptotic proteins. The release of 
mitochondrial factors in turn causes alteration of the biochemical homeostasis of the cell since 
ATP synthesisis prevented, NADH, NADPH, and GSH are oxidized and excess of ROS is 
produced. 
Finally, another key mechanism of cell death in PD is autophagy. 
Autophagy is a process induced by a change in environmental conditions, 
such as nutrient deprivation, oxidative stress and ultraviolet radiation. This 
mechanism is also been associated with normal procedures like 
development, differentiation and defense. Sometimes, in spite of offering 
protection, it may also contribute to cell damage (70). There are three arms 
of the autophagy pathways: macroautophagy, chaperone-mediated 
autophagy (CMA) and microautophagy. The first one becomes activated 
under stress conditions such as nutrient deprivations or toxins and it is 
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characterized by the formation of a autophagosome that merges with 
lysosomes (Fig. 7). 
 
Figure 7. Autophagy pathways. 
CMA involves directly lysosomal targeting and degradation of soluble, 
cytoplasmatic proteins that present a specific target sequence. This 
mechanism plays a key role in α-syn turnover and probably its pathogenic 
effects. Finally in the latter, the lysosome surrounds a targeted protein or 
organelle. All these processes maintain intracellular balance and can occur 
in every living cell. When cell homeostatic mechanism fail to comply, death is 
inevitable. This leads to the induction of mitosis of neighbouring cells in 
order to maintain tissue integrity and function. In the adult brain tissue, this 
process of replenishment cannot occur, since neurons cannot divide. 
Neurons have to adjust all their intracellular processes in order to survive for 
decades. Thus, proper autophagy regulation is essential for neuronal 
survival and its dysfunction has been entailed in neurodegenerative disease 
(71). 
The α-syn recycling is performed by the proteasome system, CMA and 
macroautophagy. The proteasome degrades only soluble forms of the 
protein. A percentage of intracellular α-syn modifies the CMA pathway, 
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having weak affinity for the CMA receptor on the lysosomal membrane. 
Instead of entering for degradation, they accumulate in the cytoplasm (72). 
Finally, the PD-related proteins PINK1 and Parkin operate as central 
components of autophagy. Overall, these studies highlight an emerging 
concept where perturbations in the function of autophagy and the lysosomal 
pathway may contribute to the development of neurodegenerative conditions 
as part of the etiology of the disease, affecting the global maintenance of 
proteostasis and catabolic processes involved in the clearance of damaged 
organelles (72). 
1.1.5. ANIMAL MODELS 
Animal models are essential research tools not only to explore the 
underlying pathology and molecular mechanisms of disorders but also to 
evaluate the potential efficacy of the interventions; and to provide an initial 
estimate of the safety margin and human dosing parameters of a drug 
candidate. There are numerous limitations to the use of such models, not the 
least of which is the inherent challenge associated with attempting to model 
complex and still poorly understood human disorders in a lower species. 
This task is particularly difficult for CNS disorders due to the poverty of 
information about the genetic and epigenetic origins and molecular 
mechanisms responsible for these disorders, the heterogeneous nature of 
many of these conditions and the subjective and sometimes contradictory 
endpoints that are used to describe their symptoms and severity (73). 
The two categories of PD models are toxin-based models and 
transgenic mice. Neurotoxic models of PD include that produced by the toxin 
6-hydroxydopamine (6-OHDA) into dopaminergic cell or terminal regions, 
most commonly used in rats, but also in mice and marmosets. The second 
one is by MPTP, which is currently almost exclusively used in mice and in a 
variety of non-human primates. However the administration of MPTP to 
various animals (monkeys, mice, cats, rats, guinea pigs, dogs, sheep, and 
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even frogs and goldfish) has been shown to also cause parkinsonian like 
motor disturbances. This neurotixin was inadvertently produced during the 
synthesis of an analog of Demerol for recreational use. Ingestion of the 
compound by young drug abusers resulted in the production of motor 
symptoms that were indistinguishable from PD. MPTP has subsequently 
been shown to be converted to MPP+ in the brain which is preferentially 
taken up into dopaminergic neurons by the DAT. Once inside the neuron, it 
blocks the ECT in the mitochondria, decreasing cellular ATP levels and 
leading to the formation of toxic ROS. It should be noted that MPTP-treated 
mice also exhibit preferential loss of cells in the SNpc and they show motor 
impairments (2). Other neurotoxins are rotenone, paraquat and maneb, 
isoquinoline derivatives, and methamphetamine. Although it is important to 
cite the attempts to produce new models with the latter toxins, so far, none 
has succeeded in generating new and reliable therapies (74, 75) (Table I). 
Table I. Differences in toxins induced animal models 
Toxin 
Time to 
greatest 
DA cell 
loss 
Striatal loss of 
dopamine Advantages Disadvantages 
6-OHDA 
in SN 42h 
Dose-dependent 
loss of DA 
innervation 
1. Full DA depletion of 
nigrostriatal pathway 
2. Mimics late-stage PD 
3. Test therapeutic 
strategies 
1. Not progressive 
2. like axotomy 
3. No extra-nigral 
pathology 
6-OHDA 
in STR 
16 
weeks 
Circumscribed loss 
of TH 
immunoreactvity at 
injection site 
1. Progressive DA cell 
loss 
2. Produced incomplete 
lesions that mimic PD 
1. Strong striatal glial 
reaction 
2. No inclusions 
3. No extra-nigral  
MPTP 24 h 
Dorsal striatum 
with sparing of 
nucleus 
accumbens 
1. Inhibits complex I 
activity 
2. Striatal TH loss  
1. Not progressive 
2. No inclusions 
Paraquat 
and 
Maneb 
7 days 
Little or no 
measurable 
changes in striatal 
DA innervation 
1. Combination of 
paraquat and maneb is 
more effective for DA 
depletion  
1. Inconsistent 
results on DA loss 
2. No inclusions 
3. No extra-nigral  
Rotenone 36 days 
or more 
Dose-dependent 
loss of TH in 
dorsal striatum 
with sparting of 
nucleus 
accumbens 
1. Inhibits  CI activity 
2. Progressive DA cell 
loss 
3. α-syn inclusions in DA 
neurons 
4. I.p. administration 
shows extra-nigral 
pathology  
1. Large variations in 
animal sensitivity 
2. Motor deficits 
have yet to be 
demostrated 
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There are relatively rare forms of PD that have been linked to genetic 
mutations. The two autosomal dominant genes are α-syn and leucine rich 
repeat kinase 2 (LRRK2). The formarmation of LBs is a hallmark pathologic 
feature of PD and point mutations or duplications are sufficient to cause PD. 
Several α-syn transgenic lines have been created and their phenotype 
heavily depends on the choice of promoter. None of the models accurately 
represent PD, while there are some dopamine-responsive functional 
abnormalities; there is no progressive loss of dopaminergic neurons. Only 
transgenic mice with the prion promoter (mPrP) exhibit the full range of α-
syn pathology that is observed in humans (76). LRRK2 is a large 
multidomain containing protein that is localized to membrane structures and 
mutations linked to PD are concentrated in the GTPase and kinase domains 
(77). Transgenic LRRK2 mice have abnormalities in the nigrostriatal system 
and behavioral deficits that are dopamine-responsive. However, they display 
a very mild phenotype with minimal evidence of neurodegeneration and are 
clearly not robust models of PD. There are several autosomal recessive 
genes that have been linked to PD and the best characterized of these are 
parkin, DJ-1 and PINK1. Knockout mice have been created for each of these 
genes but none of them exhibit nigrostriatal pathology, however they could 
be useful for the exploration of early, pre-neurodegenerative changes that 
occur in PD (75). 
• 6-OHDA INDUCED LESION 
6-OHDA is the neurotoxin par excellence to model PD in rats and is 
also being increasingly used with genetically modified mice. When 
administered systemically, 6-OHDA destroys sympathetic neuron nerve 
terminals in the peripheral nervous system. The toxin shares some structural 
similarities with dopamine and norepinephrine (Fig. 8), this is the reason 
because is preferentially transported into dopaminergic neurons by the DAT 
and in noradrenergic neurons by the norepinephrine transporters (NET). 
Part I                                                                                                               Introduction 
 
  
 28 
 
Figure 8. Comparison of the chemical structures of 6-hydroxydopamine and dopamine 
Once in the neuron, 6-OHDA accumulates in the cytosol and 
undergoes prompt auto-oxidation, promoting a high rate of H2O2 formation 
and para-quinone; so the neurotoxin can inflict damage to the 
catecholaminergic pathways by a combined effect of ROS and quinones 
(Fig. 9) (78, 79). As an additional mechanism, 6-OHDA can accumulate in 
the mitochondria, where it inhibits CI activity. The lesion obtained with 6-
OHDA is highly reproducible, which represents a considerable added value 
when new therapeutic strategies are to be investigated and clear 
neuroprotective effects must be demonstrated (80). 
 
Figure 9. 6-OHDA oxidation 
Like other parkinsonian neurotoxins, 6-OHDA can be administrated by 
systemic injection, but will not produce the desired nigrostriatal lesion. The 
toxin poorly crossed the BBB, to circumvent this problem 6-OHDA has to be 
injected stereotaxically into SN o STR to affect directly the nigrostriatal 
dopaminergic pathway. Supporting the relevance of oxidative stress in this 
model, it has been shown that mice over expressing superoxide dismutase 
and glutathione peroxidase are protected against 6-OHDA toxicity, as are 
rats treated with the antioxidant vitamin E (80). After an injection in SN, 
dopaminergic neurons start to die within the first 24h and show non-
apoptotic morphology. Maximal reduction of striatal dopamine level is 
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reached within 3–4 days after lesion, and, in most studies, residual striatal 
dopamine content is less than 20% of controls (81). 
On the other hand, when injected into the STR, 6-OHDA produces a 
massive anterograde degeneration of the nigrostriatal system which can last 
from 1–3 weeks after lesion, and the dying neurons exhibit a varied 
morphology. In addition to the lesion of the dopaminergic system, gliosis is 
also a prominent feature of the 6-OHDA model. Many data support the idea 
that the glial response in experimental models of PD, especially of microglia, 
exacerbates the degeneration of dopaminergic neurons (82). 
Unilateral injection of 6-OHDA produces a typical asymmetric circling-
motor behavior that depends on the importance of nigrostriatal lesion. This is 
possible because of the rapidity with which the toxin is metabolized. In this 
way, with a unilateral injection the healthy hemisphere could be used such 
as internal control for the lesioned one. This specific behavioral abnormality 
is most prominent after administration of drugs that stimulate dopaminergic 
receptors, such as apomorphine (rotation away from the lesion), or drugs 
that stimulate the release of dopamine, such as amphetamine (rotation 
toward the lesion), due to physiologic imbalance between the lesioned and 
the unlesioned STR (83). Quantification of this turning behavior has been 
used extensively to assess the antiparkinsonian potency of new drugs, 
transplantation, and gene therapies and to study the motor fluctuations in the 
chronic treatment with levodopa (53). Also important to remember is the 
instrumental role played by the unilateral 6-OHDA rat model in the 
identification of key neurotransmitter pathways governing the functional 
neuroanatomy of the basal ganglia. In conclusion, although this specific 
model may be more challenging to use than some others, the huge body of 
work based on its utilization represents a significant force for choosing it in a 
variety of investigations. In keeping with this, the unilateral 6-OHDA rodents’ 
model has been and continues to be one of the most popular experimental 
models of PD when it comes to the preclinical testing of new symptomatic 
therapies and neuroprotective interventions (54). 
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1.2. STRATEGIES OF NEUROPROTECTION 
At these days, the pharmacological treatment for neurodegenerative 
pathologies is only symptomatic for motor features. In PD, the depletion of 
DA is reestablished by the assumption of L-DOPA, but with the progression 
of the pathology, the number of neurons is continuously diminished and in 
this way the drug cannot be efficient because it cannot found its target. On 
the other hand, the transformation itself of L-DOPA in DA contributes to the 
increment of ROS and consequently to the progression of the 
neurodegenerative process. For all these reasons is always much more 
important try to find out a therapeutic alternative. 
 Neuroprotection can be classically defined as the consequence of any 
intervention that produces long lasting benefits by influencing etiology or 
pathogenesis through preventing disease’s onset or clinical decline. This is 
defined as the capacity of any intervention to normalize the function of 
injured (but not dead) neurons. At the bottom of the strategy there is the 
implication that neurons may be dysfunctional but not irreversibly damaged 
and therefore capable of being restored to normal functions. All these 
concepts imply that the main actors in neuroprotection are the pathogenesis 
of PD (particularly cell death) and the clinical evolution. At present, 
neuroprotective strategies in PD are not aimed at treating the consequences 
of the disease, but to interfere with the basic pathogenic mechanisms of 
nigral cell death (84). However, PD is better defined as the final 
consequence of a degenerative process linked to a special vulnerability of 
cathecholaminergic cell groups and a failure of compensatory mechanisms 
associated with the effects of ageing and brain lesions. Furthermore, the 
preservation of normal neurons’ functions can also lead to a better outcome 
and, consequently, it should be considered as an important target for any 
neuroprotective therapy. In keeping with this line of thinking, it is possible to 
lead another concept of neuroprotection such as an intervention able to 
delay PD clinical progression by directly or indirectly influencing disease 
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pathogenesis with a resultant reduction of cell death, cell damage and cell 
dysfunction. From a practical point of view, it implies that an improvement in 
general health, which can reduce the risk of vascular lesions, or in the 
ageing process, could exert a neuroprotective effect. Finally, it emphasizes 
the importance of gaining insight into the interaction between these new 
elements, PD pathogenesis and clinical expression since this could result in 
new therapeutic targets (85). Last but not least, some life style 
recommendations, such as the intake of hypocaloric and salt free diet with a 
high antioxidant content and the performance of regular physical and 
intellectual activities, might positively influence the final outcome by 
strengthening the compensatory mechanisms. All of these interventions 
have been shown to exert neuroprotective effects in experimental models by 
increasing the levels of trophic factors, by contributing to the correct 
functioning of the regenerative neural stem cells system (86). Generally a 
neuroprotection strategy can be summarized in three cardinal phases: 
 
• Primary consists in the elimination of all risk factors 
• Secondary is bind to the precocity of the diagnosis, when the 
pathology is still in an asymptomatic phase. This is at the bottom 
of an efficient strategy able to delay neuronal death. 
• Tertiary consists in the slowing down pathology progression.  
 
Many different mechanisms are involved in neurodegenerative disease 
such as excitotoxicity, ROS formation and propagation, and the activation of 
different cell death pathways. From the moment that PD is a multifactorial 
pathology, is extremely important that a new therapeutic approach has a 
large variety of target. 
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1.2.1. MULTIFUNCTIONAL PHYTOCHEMICALS 
The theory of free radicals in the ageing process was first formulated in 
the 1950s by Harman. Following studies have indicated that oxidative 
damage constitutes a mechanism of injury found in many types of age-
related diseases (87). As we age, antioxidant defenses become diminished, 
resulting in the increase of oxidative stress which is considered an important 
component in age-related diseases such as AD and PD (88). Unfortunately, 
the use of relatively safe antioxidant compounds found in the diet as a form 
of treatment in these disorders is attractive but limited by the difficulty in 
reaching an active concentration in the brain (89). Natural antioxidant 
molecules have been proposed as an alternative form of treatment for the 
prevention of these neurological pathologies. There are clear evidences that 
a diet rich in specific nutritional food groups like fruit, fish, and vegetables 
can reduce the incidence and prevalence of some of the main clinical 
features, such as neurodegenerative disorders, cardiovascular diseases, 
diabetes and cancer.  
Brassica family is the largest and most widely consumed group of 
plants in Europe and all over the world. The family includes around 375 
genera and about 3200 species characterized by different levels of nutrients. 
Because of their large and frequent consumption, they may become a 
significant source of nutrients and bioactive compounds in the daily diet. The 
beneficial effects of Brassica vegetables on human health have been linked 
to phytochemicals. They prevent oxidative stress, induce enzymes of 
detoxification, stimulate immune system, decrease the risk of cancers, inhibit 
malignant transformation and carcinogenic mutations, as well as, reduce 
proliferation of cancer cells. Brassica vegetables contain a lot of valuable 
metabolites, and a considerable source of antioxidants. Moreover, these 
vegetables are also rich in glucosinolates, which are unstable compounds 
and undergo degradation into biologically active indoles and isothiocyanates 
(ITCs) under the influence of enzyme presented in plant tissues, 
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myrosynase. These substances through the induction of enzymatic systems 
I and II phase of xenobiotics metabolism may affect the elimination or 
neutralization of carcinogenic and mutagenic factors, and consequently 
inhibit DNA methylation and cancer development (90).  
1.2.2. GLUCOSINOLATES 
Among the many varieties of vegetables, brassicaceae vegetables 
have received the most attention because of their unique constituents, 
glucosinolates. These components are abundant in edible parts and are 
regarded as most likely to maintain human health through continuous 
consumption. Glucosinolates are secondary metabolites found in 
Brassicaceae and related families, they present three different components: 
a β-thioglucose part, a sulfonated oxime, and a variable aglycone side chain 
derived from α-aminoacid. Glucosinolates, of which nearly 200 types having 
different substituents have been identified, are classifiable into three classes 
based on the structure of different amino acid precursors: aliphatic 
glucosinolates, indole glucosinolates, and aromatic glucosinolates (Fig. 10).  
 
Figure 10. Glucosinolates found in Brassicaceae vegetables 
The glucosinolates of each group are synthesized through a metabolic 
pathway that is independent and which shares a common set of enzymes 
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involved in the core structure formation of glucosinolates under genetic 
control (91). The composition and contents of glucosinolates are influenced 
by the genotype, climate and cultivation conditions including fertilization, 
harvest time and plant position (92).  
Glucosinolates are not the bioactive compounds in cruciferous 
vegetables, but their hydrolysis products, ITCs are the activated structures. 
This is important because when plant tissue damage occurs by disruption, 
glucosinolates are hydrolyzed quickly upon a β-thioglucoside glucohydrolase 
enzyme called myrosinase, resulting in production of ITCs, thiocyanates, 
nitriles, goitrin and epithionitriles, depending upon pH and other conditions 
(93). When humans consume cruciferous vegetables the only sources of 
myrosinase activity are from plant endogenous enzymes and from intestinal 
microflora. The system, in which glucosinolate and myrosinase come into 
contact when tissue destruction occurs, is called “the glucosinolate-
myrosinase system”. Presumably, glucosinolates are hydrolyzed only slightly 
under intact conditions, in which myrosinases are separated from the 
location of glucosinolates. Once tissues are mechanically damaged, 
glucosinolates are hydrolyzed intensively by myrosinases in a highly 
unstable aglycone intermediate. Although ITCs are main products from the 
myrosinase reaction, aglycones undergo rearrangement to form nitriles, 
depending on the structure of the intermediate, temperature and pH (94). 
Moreover, this glucosinolate-myrosinase system has been described as 
related to plant-insect and plant-pathogen interactions. Several studies have 
implicated glucosinolate degradation products in plant defense against 
insects, pathogens, and herbivores (95). Myrosinases are localized in 
myrosin cells, which are protein-rich idioblasts found mainly in the tissues of 
imbibed seeds. Myrosinase was localized in the epidermis and the vascular 
cambium of the radish and turnip taproots and the Japanese horseradish 
(wasabi) rhizome (96). This distribution of myrosinases, called a “double 
castle wall structure” is likely to be common among Brassicaceae 
vegetables. In the flower stalk of Arabidopsis, myrosinases are expressed 
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both in the phloem cells and the guard cells, but glucosinolates accumulate 
in the S-cells which are adjacent to the phloem cells. In fact, spatial 
separation of myrosinases from glucosinolates is the basis of the 
glucosinolate-myrosinase system. Myrosinase is destroyed by mild heating 
and cooking of vegetables, dramatically reducing isothiocyanate generation 
during chewing and digestion, however some isothiocyanate formation can 
occur in the gut due to myrosinase activity associated with endogenous 
microbes (97). 
Glucosinolates are biosynthesized from amino acids. The three 
glucosinolate subtypes have their corresponding precursors: aliphatic 
glucosinolates are derived from alanine, leucine, isoleucine, valine, and 
methionine; indole glucosinolates and aromatic glucosinolates are derived 
respectively from tryptophan and phenylalanine or tyrosine. The 
glucosinolate biosynthetic pathways comprise three independent steps: the 
chain elongation stage, formation of a core glucosinolate structure, and 
secondary modification. The chain elongation also takes place in the 
biosynthesis of aromatic glucosinolates, but does not occur in the formation 
of indole glucosinolates. 
Amino acids, including elongated ones, then undergo following step: 
the formation of core glucosinolate structure. Cytochromes P450 convert the 
amino acids to aldoximes, which are then oxidized to the activated forms by 
CYP83s. The activated forms are transformed to thiohydroximates via 
glutathione conjugation and the C-S lyase, and finally converted to the 
glucosinolate structure by the S-glucosyltransferases of the UGT74 family 
and the sulfotransferases SOTs. After the glucosinolate structure formation, 
the side chains are modified by oxygenation, hydroxylation, alkenylation, 
benzoylation, and methoxylation. The S-oxygenation of aliphatic 
glucosinolates is a common modification conducted by flavin 
monooxygenases FMOGS-OXs. The S-oxygenated aliphatic glucosinolates, 
such as glucoraphanin, are found in many Brassicaceae vegetables. Alkenyl 
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glucosinolates such as sinigrin are produced by 2-oxoglutarate-dependent 
dioxygenases AOPs from S-oxygenated glucosinolates (Fig. 11) (98). 
 
Figure 11. Schematic pathway of aliphatic glucosinolate biosynthesis. The pathway 
consists of chain elongation, glucosinoate formation, and secondary modification. 
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1.2.3. BIOLOGICAL ACTIVITY OF ISOTIOCYANATES 
ITCs are a class of secondary metabolite responsible for the bitter taste 
and pungent smell of cruciferous vegetables such as broccoli, watercress, 
mustard and wasabi (98). Disruption of plant tissue results in the hydrolysis 
of inert glucosinolates by the enzyme myrosinase (Fig. 12).  
 
Figure 12. Myrosinase-dependent formation of ITCs. 
These kinds of components have also attracted attention for the 
prevention and treatment of human disease. Humans obtain ITCs through 
the consumption of cruciferous vegetables. A large number of evidence 
indicates a positive association between increased consumption of 
cruciferous vegetables and decreased cancer risk. ITCs are reactive 
electrophiles that covalently modify proteins that will also be central to the 
effects of them in biological systems. These effects include triggering 
noxious responses, influencing carcinogen metabolism impairing tumor 
development and modifying inflammatory cytokine production. Accumulating 
evidences suggest that they exert their effects through a variety of signaling 
pathways involved in detoxification, inflammation, apoptosis, and cell cycle 
regulation. The central electrophilic carbon of ITCs (R-N=C=S) undergoes 
rapid addition reactions with biological nucleophiles, in particular, amines 
and thiols. ITCs react with amines to generate stable thiourea derivatives, 
whereas reaction with thiols generates labile dithiocarbamate adducts. 
Seminal studies by Drobnica and colleagues through the 1970's 
characterized the reactivity of a variety of ITCs with small molecules, 
peptides and proteins, and showed that they are able to react up to one 
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thousand times faster with thiol groups than with amino groups, rendering 
proteins with functional and structural cysteine residues particularly sensitive 
targets for modification (99). The tripeptide glutathione (γ-Glu-Cys-Gly) is an 
abundant physiological thiol, and catalysis by glutathione S-transferases 
ensures that a significant proportion of ITCs are initially conjugated to 
glutathione. These conjugates are rapidly effluxed from cells, and the 
removal of glutamate and glycine followed by acetylation generates a 
mercapturic acid (N-acetylcysteine isothiocyanate) that is excreted into urine. 
However, in all of these compounds the cysteine-isothiocyanate conjugate is 
able to dissociate back to the parent ITCs (100). This reversibility provides 
the opportunity for transport throughout the body, and the reaction of free 
ITCs or transfer reactions with more reactive targets (101). ITCs are 
particularly adept at inducing apoptosis. Their pro-apoptotic activity was first 
reported in the late 1990s and it provided the possibility of direct anti-cancer 
activity to complement the increased carcinogen detoxification displayed by 
these phytochemicals. Pro-apoptotic activity has often been associated with 
disruption of mitochondrial function, and in many cell lines cyt C release is 
observed quickly following ITCs exposure. Release of apoptotic mediators 
from mitochondria is regulated by the Bcl-2 family of pro- and anti-apoptotic 
proteins. A decline in levels of the anti-apoptotic proteins, as well as 
upregulation of the pro-apoptotic proteins have been reported in different 
models of isothiocyanate-induced apoptosis, suggesting that ITCs act by 
transcriptional or post-translational regulation of these proteins (99). Many 
structural and regulatory proteins have critical cysteine residues that are 
susceptible to oxidation. As a consequence, cells require a network of 
antioxidants to maintain a reducing environment. The antioxidant-response 
element (ARE) is a cis-acting DNA element essential for transcriptional 
activation of phase-II genes such as those encoding UDP-glucuronosyl 
transferase and glutathione-S-transferase and the genes for antioxidants 
such as NADPH: quinone reductase and heme oxygenase-1 (HO-1). The 
activation of ARE is dependent on the translocation of nuclear factor E2–
related factor 2 (Nrf2) into the nucleus through its release from kelch-like 
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ECH-associated protein 1 (Keap1), the cytoplasmic repressor of Nrf2. Nrf2 
binds to ARE in the nucleus and promotes the transactivation of the ARE 
coded genes (102). ITCs are known to be potent Nrf2 activators and exhibit 
anti-oxidative and anti-carcinogenic effects via the up-regulation of ARE 
driven genes (99). Even if the mechanism of interaction between ITCs and 
Keap1 is complicate and not fully understood, it might be mediated by 
activation of protein kinases, or as a direct reaction of ITCs with the sulfydryl 
groups of specific cysteine residues in Keap1, resulting in conformational 
changes that would drive the release of Nrf2 (103).  
Similar to carcinogenesis, oxidative stress and chronic inflammation are 
central in the pathogenesis of PD and other neurodegenerative diseases, 
and the protective effects of isothiocyanates are evident in models of 
nervous tissue injury and neurodegeneration. Sulforaphane, one of the most 
studied ITCs, has protective effects on neurons of the central nervous 
system decreasing both microglial activation and the upregulation of 
inflammatory markers following endotoxin injection (104). However, there are 
few studies on the detailed mechanism of neuroprotective effects of 
isothiocyanates in the central nervous system (105). The neuroprotective 
effects of sulforaphane are accompanied by activation of the transcription 
factor Nrf2 and upregulation of its target genes.  ITCs cross the cell 
membrane and accumulate in the cytoplasm where they bind to glutathione 
and other cellular thiols, reacting with the -SH groups. Although this reaction 
is reversible, it is believed to be the main driving force for accumulation of 
ITCs and for enzyme induction (106). Phase-2 enzymes are generally 
regarded as antioxidants as many of them have been proven to increase the 
cellular levels of antioxidant molecules like glutathione, or protect the cell 
from ROS and oxidizing species (107). For instance, sulforaphane was 
tested for its protective property in the ischemia reperfusion model, as 
representation for oxidative stress-mediated injury model, where the ITC 
dramatically induced phase 2 enzymes, decreasing the Keap1 protein levels 
and increasing Nrf2 nuclear translocation (106). 
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Wasabi (Wasabia japonica) is a member of the Brassicaceae family of 
vegetables, and its rhizome is a very popular pungent spice in Japan. 
Wasabi differs from other Brassicaceae species because it contains higher 
concentration of ITCs, especially long-chain ITCs. The bioactive components 
of wasabi have been identified as a series of ITC analogues, of which 6-
(methylsulfinyl)hexyl isothiocyanate (6-MSITC) (Fig. 13) is a major active 
compound (102). 
 
Figure 13. Chemical structure of 6-MSITC 
 
In this contest appears the fundamental importance to investigate if 6-
MSITC is able to interact and modify the progression of neurodegenerative 
disorders like PD. 
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2. AIM OF THE STUDY 
 
PD is a pathology is characterized by a slow and progressive loss of 
dopaminergic neurons in SN, and represents the most frequent 
representation between movement diseases.  
Also if the etiology of PD is still unclear, it is already strengthened the 
multifactorial origin of the pathology. Pathogenesis seems to be strongly 
related to oxidative stress, neurotoxicity of excitatory aminoacids and 
apoptotic mechanisms.  
Pharmacological therapies are successful only for what that concern 
motorial symptoms, but they are not powerful to prevent or arrest disease’s 
progression. In this context it is evident how important is the concept of 
neuroprotection, that aims to interfere with mechanisms subtending to 
cellular death. Iin the last decade, numerous works suggested the potential 
neuroprotective role of various phytochemical compounds such as 
cathechins of green tea, anthocyanes of red fruits and other polyphenols. 
This work aims to study mechanisms of natural compounds to prevent 
or slow down neurodegenerative diseases. This study is focused on 
neuroprotective potential of 6-(methylsulfinyl)hexyl isothiocyanate (6-MSITC) 
in an experimental in vivo model of PD. The condition was induced by 
unilateral stereotaxic injection of 6-OHDA. For this purpose, the damage was 
provoked in STR, such as nigro-striatal terminations, that permitted to obtain 
a minor entity lesion and with a major time to establish. The lesion obtained 
spreads in a backward way and the slow evolution of the pathology permits 
to evaluate the potential efficacy of treatments to contrast damage induced. 
This work has an integrated approach of behavioral assessment, 
biomolecular and immunohistochemistry techniques to evaluate 
neuroprotective effects of 6-MSITC.  
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In particular, we have used Rotarod test to assess motor coordination 
and rotational behavior induced by apomorphine injection, to estimate 
lesion’s entity and the eventually recovery after the treatment. 
After the sacrifice we used Western Blotting and immunohistochemistry 
to evaluate tyrosine hydroxylase levels in our samples. Furthermore, we 
evaluate the apoptotic process by analisys of DNA fragmentation and 
caspase-3 activation. After that we investigated how 6-MSITC is able to 
interact with cell’s redox status and GSH system. 
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3. MATERIALS AND METHODS 
 
3.1. ANIMALS AND EXPERIMENTAL DESIGN 
Male C57Bl/6 (9 weeks old, 25–30 g body weight at the beginning of 
the experiment; Harlan, Milan, Italy) mice were housed 4-5 for cage under 
12 h light/12 h dark cycle (lights on from 7:00 a.m. to 7:00 p.m.) with free 
access to food and water in a temperature (22±2°C) and humidity (60%) 
controlled room (Fig. 14). Experimental procedures were carried out in the 
light cycle (from 9:00 a.m. to 3:00 p.m.) including control groups in any tests 
utilized. In particular, the experimental protocol was based on the unilateral 
stereotaxic intrastriatal injection of 6-OHDA. Animals were randomly divided 
into 4 groups (n=10-12 per group), as follows: 6-OHDA/saline; 6-OHDA/6-
MSITC; sham/saline; sham/6-MSITC. Two groups received a 6-OHDA 
injection in the left STR, while the other two received the same volume of 
saline solution (sham groups). Each mouse served as its own control, since 
left-sided levels (ipsilateral to the lesion) were always compared to right-
sided levels (contralateral to the lesion) of the same animal. One hour after 
brain lesion, we started intraperitoneal (ip) administration of 5 mg/kg 6-
MSITC (Lkt Laboratories, St. Paul, MN, USA) or vehicle (saline) in both 
lesioned and sham mice. We injected mice twice a week for four weeks. 
Four weeks after the lesion, we assessed the extent of the lesion using the 
rotational behavior test and we also evaluated motor function on the rotarod 
apparatus (Ugo Basile, Comerio, VA, Italy). At the end of behavioral 
analysis, mice were sacrificed by cervical dislocation to perform 
immunohistochemistry and neurochemical analysis. 
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All experiments were carried out in accordance with Directive 2010/63/EU 
and Directive 86/609/CEE and approved by the corresponding committee at 
the University of Bologna (PROT. n. 15-IX/9). Care was taken to minimize 
the number of experimental animals and to take measures to limit their 
suffering. Mice were allowed to acclimatize for at least 1 week before the 
start of experiments. 
 
Figure 14. Mouse C57BL/6JOlaHad 
3.1.1. NEUROTOXIC LESION 
Animals were anesthetized under gaseous anesthesia (2% isoflurane in 
1 L/min oxygen/nitrous oxide) using a gaseous anesthesia system (Ugo 
Basile, Varese, Italy) and then mice were positioned on a mouse stereotaxic 
frame (myNeuroLab, Leica-Microsystems Co, St. Louis, MO, USA). 
Anesthesia was maintained with 1.5% isofluorano/O2 (1L/min). The scalp 
was incised to reveal the skull and recognize the bregma to set coordinates. 
6-OHDA (Sigma-Aldrich, St. Louis, MO, USA; Fig. 15) was injected into 
the left STR, using the stereotaxic mouse frame and a 10 µL Hamilton 
syringe. 6-OHDA was dissolved at a concentration of 4 µg/µL saline in 
0.02% ascorbic acid just before the use and 2 µL was injected at a rate of 
0.5 µL/min.  
 
Figure 15. 6-OHDA structure. 
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The needle was left in place for 3 min after the injection before slow 
retraction, followed by cleaning and suturing of the wound (Histoacryl, 
Aesculap AG, Germany). Sham mice received the equivalent volume of 
saline into the left STR. The injection was performed at the following co-
ordinates with a flat skull position:  
AP  + 0.50 
ML  - 2.00 
DV  - 2.50 
 
After the surgery mice were collocated under an irradiating lamp to 
promote the recovery for the time required. 
3.1.2. TREATMENT WITH 6-(METHYLSULFINYL)HEXYL 
ISOTHIOCYANATE 
The treatment with 6-MSITC (6-(methylsulfinyl)hexyl isothiocyanate, 
LKT Laboratories, Inc., St. Paul, MN, USA) was carried out with ip 
administration of 5 mg/kg or vehicle in both lesioned and sham mice from 1 
hour after the surgery and then two times a week for four weeks (Fig. 16). 
 
Figure 16. 6-MSITC structure 
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3.1.3. ROTAROD TEST 
Rotarod test was used to evaluate the presence and severity of the 
lesion induced; the time that animals spent on the instrument is indicative of 
motor coordination and balance. The test was carried out using a 
commercially available mice rotarod apparatus (Ugo Basile, Varese, Italy; 
Fig. 17). The unit consists of a rotating spindle divided into 5 lanes by gray 
plastic dividers, a power source for turning the spindle and grids beneath the 
rotating roller where mice can safely fall, and the time latency to fall (s) is 
automatically recorded.   
 
Figure 17. Rotarod 
METHOD 
Animals were transferred to the experimental room at least 1h before 
the test in order to let them acclimatize to the test environment. All scores 
were assigned by the same observer who was unaware of the animal 
treatment. The test was accomplished 4 weeks after the surgical procedure. 
All mice were pre-trained for 2 days in order to reach a stable 
performance. The apparatus tests five mice at one time, with one mouse in 
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each section of the rod. Each animal was given three independent trials, 
each lasting 180 s (with a 20 min inter-trial period). Mice were mounted on 
the rod and the apparatus turned on to a fixed speed of 22 rpm. The latency 
of fall from the apparatus was recorded. Values were expressed as mean of 
retention time on the rotating bar over the three test trials. 
3.1.4. ROTATIONAL BEHAVIOR 
Apomorphine-induced rotations were determined 4 weeks after the 
surgical procedure (Sigma; Fig. 18). Apomorphine is a direct dopamine 
receptor agonist; it is able to induce contralateral rotation. This behavior 
suggests the presence of a different number of dopaminergic receptors in 
the nigro-striatal pathway in mice lesioned by 6-OHDA. Indeed, the 
dopaminergic agonist stimulates in a massive way the healthy hemisphere 
than the lesioned one. For this reason the roditor turns in the contralateral 
side, that is the healthy one. 
 
Figura 18. Apomorphine structure. 
METHOD 
Animals were transferred to the experimental room at least 1h before 
the test in order to let them acclimatize to the test environment. All scores 
were assigned by the same observer who was unaware of the animal 
treatment. The test was accomplished 4 weeks after the surgical procedure. 
Briefly, mice received a subcutaneous injection of apomorphine (0.05 
mg/kg saline). They were acclimatized in plexiglass cylinders for 5 min prior 
to testing. After apomorphine administration, full body ipsilateral and 
contralateral turns were recorded using an overhead videocamera over a 
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period of 10 minutes. Subsequently, each 360° rotation of the body axes 
was manually counted as a rotation. Values were expressed as mean of 
contralateral turns collected during 10 minutes. 
3.1.5. SACRIFICE AND TISSUE PREPARATION FOR 
IMMUNOHISTOCHEMISTRY AND NEUROCHEMICAL 
ANALYSIS 
Once behavioral analysis was completed, mice were deeply 
anesthetized and sacrificed by cervical dislocation and some of them were 
perfused with 4% of paraformaldehyde. The brains were removed and were 
immersed in the fixative solution for 48 h. The non-perfused brains were 
rapidly removed and placed into dry-ice. The right and left STR and SN were 
dissected on an ice-cold plastic dish. Samples were then snap frozen in 
liquid nitrogen, and kept at −80°C until analysis. Tissues were homogenized 
in lysis buffer (50 mM Tris, pH 7.5, 0.4% NP-40, 10% glycerol, 150 mM 
NaCl, 10 µg/ml aprotinin, 20 µg/ml leupeptin, 10 mM EDTA, 1 mM sodium 
orthovanadate, 100 mM sodium fluoride), and protein concentration was 
determined by the Bradford method. 
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3.2. WESTERN BLOTTING 
Activation of tyrosine hydroxylase (TH) was evaluated by Western 
Blotting, useful technique to quantify proteins that recognize a specific 
antibody. 
METHOD 
Samples (30 µg proteins) were added to the Loading Buffer 6x (4x tris 
HCl/SDS, pH 6.8; glycerol; SDS; DTT; bromophenol blue) and then 
separated on 12% SDS-polyacrylamyde gels (Bio-Rad, Hercules, CA, USA) 
in Running Buffer (25 mM Tris; 192 mM Glycine; 0,1% (w/v) SDS pH 8,3) for 
30 minutes at 200 V, and electroblotted onto 0.2 µm nitrocellulose 
membranes in Blotting Buffer (25 mM Tris; 192 mM Glycine; 20% (v/v) 
MeOH pH 8,3) for 1 hour at 100 V. After the transfer, membranes were 
incubated for 2 hours in Block Solution (5% no-fat powder milk; TBS; 0.05% 
Tween 20) to block aspecific binding sites. Membranes were incubated 
overnight at 4°C with primary antibody recognizing TH (1:1000; Millipore). 
The day after membranes were washed with TBS-T (TBS + 0.05% 
Tween20), and then incubated with a horseradish peroxidase (POD) linked 
anti-rabbit secondary antibody (1:2000; GE Healthcare, Piscataway, NJ, 
USA) for 1 hour at room temperature (RT). Immunoreactive bands were 
visualized by enhanced chemiluminescence (ECL; Pierce, Rockford, IL, 
USA). The same membranes were stripped (100 mM β-mercaptoethanol; 
2% SDS; 62,5 mM Tris pH 6.7) and reprobed with a β-actin antibody 
(1:1000; Sigma-Aldrich) 2 hours at RT and then incubated with a 
horseradish peroxidase (POD) linked anti-mouse secondary antibody 
(1:2000; GE Healthcare, Piscataway, NJ, USA) for 1 hour at RT. Data were 
analyzed by densitometry, using Quantity One software (Bio-Rad). Values 
were normalized to corresponding β-actin and expressed as fold increase 
versus respective contralateral intact site. 
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3.3. DNA FRAGMENTATION 
The involvement of apoptotic process after the lesion induced was 
evaluated by the determination of cytoplasmatic histone-associated DNA 
fragments using the Cell Death Detection ELISAPLUS kit (Roche 
Diagnostics, Mannheim, Germany) and according to the protocol from the 
company. The assay is based on a quantitative sandwich-enzyme-
immunoassay principle using mouse monoclonal antibodies directed against 
DNA and histones, respectively. This allows the specific determination of 
mono- and oligonucleosomes (histone-associated DNA fragments) in the 
fraction of tissue lysates (Fig. 19). 
METHOD 
Aliquots with lysates corresponding to 80 µg of proteins were used at 
each reaction. The amount of nucleosomes demonstrating DNA degradation 
was quantified by POD retained in the immunocomplex. POD was 
determined photometrically at 405 nm with 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) as a substrate by a microplate reader 
(GENios, TECAN®, Männedorf, Switzerland) after 15 min of substrate 
reaction time. Values are expressed as mean of Optical Density (OD) of 
each experimental group. 
 
 
 
 
 
 
 
Figura 19. Mechanism of function ELISA kit. 
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3.4. CASPASE-3 ACTIVATION 
Caspase-3 enzyme activity was determined using a protocol adapted 
by Movsesyan et al. (108). The assay is based on the hydrolysis of acetil-
Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) moiety by caspase-3 with 
the liberation of pNA (Fig. 20).  
 
 
 
 
 
 
 
 
 
 
METHOD 
Briefly, tissue lysates of SN were incubated with assay buffer (50 
mmol/L Hepes, pH 7.4; 0.2% CHAPS; 20% sucrose; 2 mmol/L EDTA; and 
10 mmol/L dithiothreitol) and a 50 µmol/L concentration of chromogenic pNA 
specific substrate (Z-Asp-Glu-Val-Asp-pNA; AlexisBiochemicals, San Diego, 
CA, USA). In a final volume of 100 µL (containing 120 µg of protein), each 
test sample was incubated for 3 h at 37°C. The amount of chromogenic pNA 
released was measured with a microplate reader (GENios, TECAN®) at 405 
nm. Values are expressed as mean of Optical Density (OD) of each 
experimental group. 
 
APOPTOSIS 
INDUCTION 
PROTEASE 
ACTIVATION 
SUBSTRATE 
SUBSTRATE + 
Figure 20. Caspase-3 activation analisys.
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3.5. REDOX STATUS EVALUATION 
The redox status, in terms of ROS formation, was measured as 
described previously (109), based on the oxidation of 2′7′-
dichlorodihydrofluorescein diacetate (DCFH-DA) to 2′7′-dichlorofluorescein 
(DCF). Briefly, the reaction mixture (60 µL) containing 2 mg/mL of DCFH-DA 
was incubated for 30 min to allow the DCFH-DA to be incorporated into any 
membrane-bound vesicles and the diacetate group to be cleaved by 
esterases. After 30 min of incubation, the conversion of DCFH-DA to the 
fluorescent product DCF was measured using a microplate reader (GENios, 
TECAN®) with excitation at 485 nm and emission at 535 nm. Background 
fluorescence (conversion of DCFH-DA in the absence of homogenate) was 
corrected by the inclusion of parallel blanks. Values were normalized to 
protein content and expressed as mean of fluorescence intensity arbitrary 
units (UF) of each experimental group. 
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3.6. GLUTATHIONE CONTENT 
GSH content was estimated using the protocol described earlier (110). 
Briefly, aliquots of 50 µL of samples were precipitated with 100 µL of 
sulfosalicylic acid (4%). The samples were kept at 4°C for at least 1h and 
then subjected to centrifugation at 3000 rpm for 10 min at 4°C. A volume of 
25 µl of the assay mixture and 50 µL of 5-5'-dithio-bis (2-nitrobenzoic acid) 
(4 mg/mL in phosphate buffer, 0.1 M, pH 7.4) was made up to a total volume 
of 500 µL. The yellow color that developed was read immediately at 412 nm 
(GENios, TECAN®) and results were calculated using a standard calibration 
curve. Values are expressed as mmol GSH/mg of total lysate proteins per 
assay. 
 
3.6.1. GLUTATHIONE-S-TRANSFERASE AND GLUTATHIONE 
REDUCTASE ACTIVITIES 
GST activity was assessed by the ability to conjugate GSH to 1-chloro-
2,4-dinitrobenzene (CDNB), as previously shown (111). Tissue lysates were 
added to 0.1 mol/L potassium phosphate 1 mmol/L EDTA with 20 mmol/L 
GSH and 20 mmol/L CDNB. The rate of appearance of the GSH-CDNB 
conjugate was measured at 340 nm (GENios, TECAN®).  
GR activity was determined using the Glutathione Reductase Assay Kit 
according to the manufacturer’s instructions (Sigma-Aldrich). Briefly, the 
assay mixture consisted of phosphate buffer (pH 7.6), EDTA (1 mM), 
oxidized GSH (2 mmol/L) and NADPH (2 mmol/L). GR was determined by 
measuring the disappearance of NADPH at 340 nm (GENios, TECAN®).  
The specific activities of GST and GR are expressed as enzyme units 
mL-1/mg of total lysate proteins per assay. 
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3.7. IMMUNOISTOCHEMYSTRY 
Fixed brains were sliced on a vibratome (Leika Microsystems, Milan, 
Italy) at 40 µm thickness. After deparaffinization, endogenous peroxidase 
was quenched with 3% hydrogen peroxide (H2O2). Non-specific adsorption 
was minimized by incubating the section in 10% normal goat serum for 30 
min. Sections were then incubated overnight at 4°C, with a rabbit anti-TH 
antibody (1:500; Millipore, Temecula, CA, USA), rinsed in TBS, and re-
incubated for 1 h, at RM, with a goat biotinylated anti-rabbit IgG antibody 
(Vector Laboratories, Burlingame, CA, USA). Finally, sections were 
processed with the avidin-biotin technique and reaction products were 
developed using commercial kits (Vector Laboratories). To verify the binding 
specificity, some sections were also incubated with only primary antibody (no 
secondary) or with the secondary antibody (no primary). In these situations, 
no positive staining was found in the sections, indicating that the 
immunoreactions were positive in all experiments carried out. 
Image analysis was performed by a blinded investigator, using an Axio 
Imager M1 microscope (Carl Zeiss, Oberkochen, Germany) and a 
computerized image analysis system (AxioCam MRc5, Zeiss) equipped with 
dedicated software (AxioVision Rel 4.8, Zeiss). After defining the boundary 
of the SN at low magnification (2.5x objective), the number of TH-positive 
cells in the SN was counted bilaterally on at least four adjacent sections at a 
higher magnification (40x objective). Neuronal survival in the SN was 
expressed as the percentage of TH-positive neurons on the lesioned side, 
with respect to the contralateral, intact side. In the absence of a stereological 
count, this approach was chosen to avoid methodological biases due to 
interindividual differences, and has been previously used to assess the 
extent of 6-OHDA-induced lesion in the SN (112). The intensity of TH 
immunoreactivity in STR was measured using AxioVision Rel software 
(Zeiss) and results were expressed as percentage of TH density on the 
lesioned side with respect to the contralateral side. 
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3.8. STATISTICAL ANALYSIS 
Data are reported as mean ± SEM. Statistical analysis was performed 
using one-way ANOVA with Bonferroni post hoc test. Differences were 
considered significant at p<0.05. Analyses were performed using PRISM 5 
software (GraphPad Software, La Jolla, CA, USA). 
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4. RESULTS 
 
Neuroprotective effects of 6-MSITC were evaluated in a mouse model 
of PD by intracranical injection of 2 µL of 6-OHDA at 4 µg/µL in the left STR 
of C57BL/6 mice. 6-MSITC (5 mg/kg) was injected by ip, from one hour after 
the surgery twice a week until the end of the experiment (4 weeks). Animals 
were divided in four experimental groups: one group has received 
physiological solution and was treated with the same solution (Sham/saline); 
one group has received physiological solution and then was treated with 
injection ip of 6-MSITC (Sham/6-MSITC); one group was lesioned with 6-
OHDA and then has received physiological solution as treatment (6-
OHDA/saline); and finally one group that has received intracranical injection 
of neurotoxin and then was treated with 6-MSITC (6-OHDA/6-MSITC). 
Initially we conducted a behavioral investigation after 6-MSITC 
treatment in our model. In order to do this, we used Rotarod to test animal’s 
ability to coordinate their movements on the rolling rod. The time taken to 
stay on the rotating rod was significantly decreased (p<0.05) in the 6-
OHDA/saline group when compared with the Sham/saline group, while no 
significant difference in motor coordination was observed in the Sham/saline 
group as compared to the 6-OHDA/6-MSITC group. Moreover, the latency 
time to fall off was signifintally increased in 6-OHDA/6-MSITC group with 
respect to 6-OHDA/saline group (p<0.05; Fig. 21a). Behavioral quantification 
of dopamine depletion, done by apomorphine-induced rotations 4 weeks 
after the lesion, demonstrated a significant increase in the number of 
apomorphine induced rotations in lesioned mice compared with sham 
groups (p<0.001 Sham/saline vs 6-OHDA/saline; p<0.05 Sham/saline vs 6-
OHDA/6-MSITC). More interestingly, statistical analysis of the total rotations, 
showed that the 6-OHDA/6-MSITC group exhibited a significant decrease of 
asymmetric motor behavior compared to the 6-OHDA/saline group (p<0.05; 
Fig. 21b) 
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Figure 21. Effects of 6-MSITC on motor coordination and apomorphine-induced rotational 
behavior in 6-OHDA mice. a. The latency to fall (s) from rotarod spindle at constant speed (22 
rpm-cut off 180 s) was recorded. Values are experessed as mean±SEM (n=10) of retention time 
(s) on the rotating bar. b. the number of ipsi and contralateral rotations was counted for 10 min. 
values are expressed as mean±SEM (n=10) of contralateral turns collected during 10 minutes. 
(a: *p<0.05, 6-OHDA/saline vs sham groups; §p<0.05, 6-OHDA/6-MSITC vs 6-OHDA/saline; b: 
***p<0.001, 6-OHDA/saline vs sham groups; §p<0.05, 6-OHDA/6-MSITC vs 6-OHDA/saline and 
saline groups; ANOVA, post-hoc test Bonferroni).  
 
Four weeks after the lesion, mice were sacrificed; SN and STR tissues 
were extracted and we proceeded with biomolecular analysis. In first 
instance, we evaluated tyrosine hydroxylase (TH) levels in SN e STR, to 
evaluate dopamine synthesis. By immunohistochemical analysis we 
demonstrated that lesioned animals showed a consistent reduction of TH-
positive cells in the left SN, compared to the intact side, with a consistent 
neuronal loss (p<0.001; Fig. 22a). 6-MSITC treatment helped to preserve the 
integrity of nigrostriatal tract producing a significant decrease of 
dopaminergic cell loss in the SN (p<0.01 6-OHDA/saline vs 6-OHDA/6-
MSITC).  
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Figure 20. Effects of 6-MSITC on TH expression in 6-OHDA lesioned mice. a. Top: 
representative photomicrographs of brain coronal sections containing both ipsilateral and 
contralateral SN in different treatments groups. Scale bar 100 µm. Bottom: histogram 
representing dopaminergic cell survival in the SN. b. Left: representative photomicrographs of 
STR sections in different treatments groups. Scale bar 100 µm. Right: quantification of striatal 
TH fiber densities. Values are expressed as mean±SEM (n=10) of the percentage of surviving 
TH-positive cells (a) or density (b) of the lesioned side compared to the intact hemisphere (a: 
***p<0.001, 6-OHDA/saline vs sahm groups; §§p<0.01, 6-OHDA/6-MSITC vs 6-OHDA/saline; b: 
**p<0.01, 6-OHDA/saline vs sham groups; *p<0.05, 6-OHDA/6-MSITC vs sham groups; 
ANOVA, post-hoc test Bonferroni). 
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TH  
62 kDa 
As shown in figure 22b, immunohistochemical detection of TH fiber 
staining in striatal tissue sections revealed that 6-OHDA reduced 
significantly the TH immunostaining in dopaminergic terminals (p<0.01). 
Although 6-MSITC slightly ameliorated the loss of TH fibrous staining, the 6-
OHDA/6-MSITC group was significantly different from sham groups 
(p<0.05). 
We also performed Western Blotting analysis for TH protein that 
confirmed what we have seen before with the immunostaining. 6-OHDA 
treatment induced a significant loss of TH immunoreactivity in the SN and 
STR (p<0.05; Fig. 23a and 23b), which was completely attenuated in the SN 
by 6-MSITC treatment (p<0.05; Fig. 23a).  
 
 
 
 
 
 
 
 
 
Figure 23. Effects of 6-MSITC on TH expression in 6-OHDA lesioned mice, valuation by 
Western Blotting. a, b. Top: Representative images of the protein expression in SN (a) and in 
STR (b). Bottom: Quantitative analysis of the Western Blot results for TH levels in SN (a) and 
STR (b). The graphs show densitometry analysis of the bands appertaining to the protein of 
interest. The values result from normalization of the ratio between the density of the band of 
interest and the density of β-actin, compared to the corresponding ratio in the intact side. 
Values are expressed as mean of fold increase±SEM (n=10) (a: *p<0.05, 6-OHDA/saline vs 
Sham/saline; §p<0.05, 6-OHDA/6-MSITC vs 6-OHDA/saline; b: *p<0.05 6-OHDA/saline vs 
Sham/saline; ANOVA, post-hoc test Bonferroni). 
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Subsequently, we investigated cell death caused by 6-OHDA, through 
the analysis of DNA fragmentation and caspase-3 activation. To quantify 
DNA fragmentation, we used an ELISA assay which measures low 
molecular weight histone-associated DNA. In our experimental model, 6-
OHDA injection caused an increase of DNA fragmentation in SN samples 
compared to sham groups (p<0.01, Fig. 24a). More interestingly, 6-MSITC 
significantly blocked 6-OHDA-induced DNA fragmentation (p<0.01). We 
confirmed this result through the evaluation of caspase-3 activation by a 
colorimetric assay. As shown in figure 24b, following the injection of 6-
OHDA, we detected a robust activation of the main effector of apoptotic cell 
death in SN sample (p<0.01). Concordantly with its inhibition of DNA 
fragmentation, 6-MSITC significantly blocked the 6-OHDA-induced caspase-
3 activation (p<0.05). 
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Figure 24. Effects of 6-MSITC on DNA fragmentation and caspase-3 activation in SN of  
6-OHDA lesioned mice. a. 6-OHDA injection significantly increased DNA fragmentation in 
lesioned mice compared to sham groups, on the other hand, 6-MSITC treatment is able to 
reduce the levels of DNA fragmentation. b. 6-OHDA injection significantly increased caspase-3 
activation, while 6-MSITC treatment is able to counteract this effects. Values are expressed as 
mean±SEM (n=10) of optical density (OD) of each experimental group (a: ***p<0.001, 6-
OHDA/saline vs Sham/6-MSITC; **p<0.01, 6-OHDA/saline vs Sham/saline; §§p<0.01, 6-
OHDA/6-MSITC vs 6-OHDA/saline; b: **p<0.01, 6-OHDA/saline vs sham groups; §p<0.05,  6-
OHDA/6-MSITC vs 6-OHDA/saline; ANOVA, post-hoc test Bonferroni). 
We also investigated the potential effects of 6-MSITC on the cellular 
redox status, because ROS generated in PD brains trigger oxidative cellular 
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stress and consequent cell death in dopaminergic neurons. As an index of 
redox status, we utilized the fluorescent probe 2’7’-
dichlorodihydrofluorescein diacetate (DCFH-DA) to measure ROS levels in 
the SN. As shown in figure 25a, neurotoxin intrastriatal injection induced a 
significant change in redox status (p<0.001), while this effect was efficiently 
contrasted by 6-MSITC administration (p<0.001). 
Furthermore, we decided to investigate endogenous antioxidant 
balance by the activation of GSH system. GSH system is responsible for 
neutralization of peroxide and maintenance of protein thiols in the reduced 
state. GSH content resulted significantly decreased in the 6-OHDA/saline 
group as compared to the Sham/saline group (p<0.05; Fig. 25b); in turn 6-
MSITC consistently protected against the oxidative stress induced by 6-
OHDA, in this way is able to maintain GSH close to baseline values 
(p<0.05). 
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Figure 25. Effects of 6-MSITC on redox status and GSH content in SN of 6-OHDA lesioned 
mice. a. 6-OHDA injection induced a consistent increase in oxidative stress that it is 
reestablished by 6-MSITC treatment. Values are expressed as mean±SEM (n=10) of 
fluorescence intensity arbitrary units (UF). b. GSH content resulted significantly decreased after 
the lesion and the treatment with 6-MSITC is able to restore baseline levels. Values are 
calculated using a standard calibration curve and expressed as mmol GSH/mg protein. (a: 
***p<0.001, 6-OHDA/saline vs sham groups; §§§p<0.001, 6-OHDA/6-MSITC vs 6-OHDA/saline; 
b: *p<0.05, 6-OHDA/saline vs sham groups; §p<0.05, 6-OHDA/6-MSITC vs 6-OHDA/saline; 
ANOVA, post-hoc test Bonferroni).  
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Finally, in view of the importance of GSH-dependent antioxidant 
enzymes, such as glutathione-S-transferase (GST) and glutathione 
reductase (GR), for cellular defense against oxidative damage, we 
investigated the activities of these enzymes. Especially, the primary role of 
GST is to detoxify xenobiotics by catalyzing the nucleophilic attack by GSH, 
in order to inactivate a number of oxidising species. The enzyme GR is also 
important in GSH homeostasis: it regenerates GSH from the oxidized form 
(GSSG). We observed that 6-OHDA/saline group showed alterations of brain 
antioxidant status compared to sham group with a decrease of GST activity 
(p<0.01; Fig. 26a) and an increase in 6-OHDA/6-MSITC group (p<0.05). The 
evaluation of GR activity demonstrated the same results, with a decreasing 
activity in 6-OHDA/saline group compared to sham group (p<0.01; Fig. 26b), 
and the consequent increase after the 6-MSITC treatment (p<0.05). 
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Figure 26. Effects of 6-MSITC on GST and GR activities in SN of 6-OHDA lesioned mice. 
The 6-OHDA intrastriatal injection determined a significant decreased of GST and GR activities 
that were reestablished by 6-MSITC treatment. Values are expressed as mean±SEM (n=10) of 
enzyme units/mg of proteins. (a: **p<0.01, 6-OHDA/saline vs Sham/6-MSITC; §p<0.05, 6-
OHDA/6-MSITC vs 6-OHDA/saline; b: **p<0.01, 6-OHDA/saline vs sham groups; §p<0.05, 6-
OHDA/6-MSITC vs 6-OHDA/saline; ANOVA, post-hoc test Bonferroni).   
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5. DISCUSSION 
 
One of the major bioactive component in wasabi roots is the 
isothiocyanate 6-MSITC (105). Several studies have shown that 6-MSITC is 
rapidly accumulated to very high levels in a variety of cell types, through its 
conjugation with cellular GSH (113). Animal experiments have indicated that 
6-MSITC, such as its analogues, can be absorbed, reach micromolar 
concentration in the blood and accumulate in tissues where it is maintained 
to achieve protective effects (114). In addition, many in vivo studies suggest 
the ability of sulforaphane, a 6-MSITC analogue, to reach CNS were it could 
display protective effects. In this context, the isothiocyante sulforaphane 
presents many advantages, such as  the potential ability to penetrate the 
BBB and deliver its neuroprotective effects in the CNS with a good 
pharmacokinetics (1). On the basis of its structural similarity to sulforaphane, 
we decided to study the neuroprotective effects of 6-MSITC.  
The pathogenesis of many neurodegenerative diseases, including PD, 
may involve the generation of ROS, which causes oxidative stress (36). 
Oxidative stress and the depletion of GSH are both early biochemical events 
associated with PD. In particular, the loss of GSH and the impairment of the 
antioxidant systems based on GSH have been shown to trigger active 
dopaminergic cell death (41).  
This study demonstrated that the preventive effect of 6-MSITC is 
closely related to the protection of nigrostriatal dopaminergic neurons from 
the neurotoxicity induced by 6-OHDA in the mouse brain. Furthermore, the 
present results suggest that the activation of the GSH-dependent antioxidant 
systems is involved in the neuroprotective effects of 6-MSITC.  
In views of our findings, the levels of GSH, GR and GST in the SN of 6-
OHDA-lesioned mice are obviously lowered, and this progressive reduction 
in antioxidant scavenging capacity induced by 6-OHDA is well documented 
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in the literature (115). 6-MSITC treatment strongly decreased ROS formation 
and increases GSH levels and GR and GST activities in the SN when 
compared with the 6-OHDA/saline group, indicating that the inhibition of the 
oxidative stress response in 6-OHDA-lesioned mice is one of the main 
mechanisms involved in its neuroprotective effect. These results are 
supported by Mizuno et al (105), who have shown that 6-MSITC prevents 
the induction of oxidative stress by cytotoxicity in rat striatal cultures by 
raising the intracellular GSH content via an increase in γ-glutamylcysteine 
synthetase expression, induced by the activation of the Nrf2-ARE 
detoxification pathway. 
Alteration in the GSH/GSSG ratio can negatively impact the structural 
and mechanistic integrity of the cells, thereby impairing brain function and, 
ultimately, neuronal viability. GSH not only remove ROS but also directly or 
indirectly regulates the activity of a number of key enzymes (GSTs, 
glutathione peroxidases, and lipoxygenases), that modulate cell survival 
(116). 
The concept that the 6-OHDA intrastriatal injection causes 
dopaminergic neurons death and dysfunction in the SN is mainly supported 
by the decrease in the number of TH immunoreactive cells was sustained by 
Blandini et al. who asserted that TH decrease might reflect a loss of 
phenotype, so dopaminergic cells are present but no longer able to express 
TH, rather than the real damage to cells and terminals (112). For this 
reason, we evaluated the induction of apoptosis in our experimental model 
and we found that 6-OHDA induced toxicity that involves the activation of 
caspase-3, which in turn activates the enzyme responsible for apoptotic 
DNA fragmentation. Based on these results, we can suggest that the 
decrease of caspase-3 activation and DNA fragmentation are strongly 
involved in the 6-MSITC mechanism of neuroprotection.  
The preservation of functional nigral neurons contributed to the 
reduction of behavioral abnormalities induced by 6-OHDA. Our results 
demonstrate that hemiparkinsonian mice exhibited significant changes in 
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apomorphine-induced rotation after 6-OHDA intrastriatal administration. 6-
MSITC induced a partial recovery in the rotational behavior test, in fact we 
still found a significant difference between the 6-OHDA/6-MSITC group and 
the sham operated mice. However, the 6-OHDA/6-MSITC group displayed a 
significant reduction in apomorphine-induced rotations as compared to the 6-
OHDA/saline group. The rotarod test has been used as a drug free test for 
unilaterally 6-OHDA-lesioned animals to assess coordination and balance 
that permits to use for detection in loss of TH-immunoreactive cells in the SN 
(117). Our results showed that the time spent on the rotating rod was lower 
in 6-OHDA-lesioned mice, and more interesting, that 6-MSITC treatment 
significantly improved mice’s performance.  
It is important to underlie that 6-MSITC induced in TH immunostaining 
an increased expression in the SN but had no effect in the STR. Probably 
the absence of protection in the STR reflects the lack of complete recovery 
shown in rotational behavior test. Indeed, it is known that nigral 
dopaminergic neurons release dopamine not only from their axons projecting 
to the STR but also from their dendrites (118). Based on these 
considerations, 6-MSITC could strengthen the dopamine release 
demonstrating a crucial role in dopaminergic activity in the SN. 
 Taken together, the results of the present study highlight that the 
administration of 6-MSITC for one month is able to exert neuroprotective 
effects in the 6-OHDA model of PD. 6-MSITC treatment results in a 
significant decrease in oxidative stress and apoptotic cell death, leading to 
an improvement of behavioral impairments, in particular motor deficits.  
It is known that oxidative stress is involved in both the initiation and the 
progression of PD (36, 40). At this regard, although the greater part of 
dopaminergic neuron loss has already occurred at the time of diagnosis of 
PD, maintenance of the redox status of the remaining dopaminergic neurons 
could slow the progression of this neurodegenerative disease. In conclusion, 
our results suggest that this isothiocyanate may be a promising 
neuroprotective compound against neurodegeneration that occurs in PD.  
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PART II 
 
1. INTRODUCTION 
1.1. CEREBRAL ISCHEMIA 
More than any other organ of the body, brain integrity depends on the 
continuous blood supply of oxygen and glucose for covering the energy 
demands of the tissue. Cessation or severe reduction of blood flow results in 
a rapid biochemical and functional deficits which become irreversible unless 
blood flow is promptly restored.  
With regard to the pathophysiology of cerebral ischemia, it can 
distinguish three major categories of flow reduction: transient global 
ischemia, permanent or transient focal ischemia, and microembolism. The 
most important clinical cause of global ischemia is cardiac arrest which 
induces a complete cessation of cerebral blood flow. Global ischemia also 
results from strangulation, severe shock or intracranical hypertension, but 
under these conditions flow decline is incomplete and heterogeneous. Focal 
brain ischemia is most frequently caused by thrombotic occlusion of the 
middle cerebral artery. Finally, microembolism, leading to multiple ischemic 
microfoci is caused by fat microemboli after bone fractures, by release of 
platelet aggregates and thrombotic materials from ulcerating atherosclerotic 
plaques or by air bubbles during cardiac surgery.  
All these ischemic conditions exhibit different pathophysiology and 
require different therapeutic approaches (119). 
In focal ischemia, the reduction of blood flow is most severe in the 
center of the region of the occluded artery. This is basically different from the 
incomplete global ischemia in which ischemia is most pronounced in the 
peripheral borderzone (120). The size of the ischemic region depends on the 
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efficacy of collateral blood supply. In the brain there are three major vessels 
– anterior, middle and posterior cerebral arteries – interconnected by the pial 
network of Heubner’s anastomoses. Blood supply by this system depends 
on the anatomical configuration of the network, the vascular tone, blood 
viscosity and blood pressure (121). Under adverse conditions, ischemia may 
develop in the total distribution of the occluded vessel (maximal infarct), but 
the ischemic region may also be very small when collateral blood supply is 
optimal (minimal infarct) (122). 
After an ischemic episode, is frequent that some brain regions are 
going to lose their property and the ability to work properly. In this contest 
appears clearly the importance of a rapid and efficient way of intervention, 
but also the importance of an efficient neuroprotective system able to 
prevent or at least to limit the damage bounded to a cerebral stroke event. 
As enunciated before, there are two main types of stroke: hemorrhagic 
and ischemic (Fig. 27).  
 
Figure 27. Ischemic and hemorrhagic strokes. On the left is showed a representation of 
ischemic stroke, after blood vessel blockage, there is a lack of blood flow to affected the area. 
On the right is represented an example of hemorrhagic stroke where the vessel’s rupture is 
responsible of a leakage of blood. 
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The first case can results from a variety of conditions including 
uncontrolled hypertension and aneurysm. The hemorrhagic strokes in turn 
could be intracerebral or subarachnoid, which are associated with brain 
tissue damage by the rupture of a cerebral artery within or on the surface of 
the brain, respectively. On the other hand there are two kind of ischemic 
stroke: thrombotic and embolic; together the two types represent 
approximately 85% of all cases of strokes. Usually thrombotic strokes occur 
in the night or early in the morning because of a thrombus forming in an 
artery inside or leading to the brain mainly as a result of atherosclerosis. 
This type of stroke is further classified in lacunar and non-lacunar strokes. 
Lacunar infarcts are small and present a diameter minor of 20 millimeter 
usually are observed in the deep cerebral white manner or basal ganglia 
probably for the occlusion of a single small artery feeding the subcortical 
areas of the brain. For what that concern the embolic strokes, they occur 
when an embolus travels through the bloodstream until it enters in a vessel 
that is too tight to let it pass. The consequence is the complete absence of 
blood supply in the region of the brain usually feed by the vessel damaged 
(123). 
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1.1.1. INCIDENCE AND EPIDEMIOLOGY 
Ischemic stroke is the third leading cause of death and the main cause 
of permanent adult disablement in industrialized countries (124). Also called 
brain attack, victims may suddenly manifest paralysis, impaired speech, or 
loss of vision due to the interruption of blood flow caused by thrombosis or 
embolism (125). Less frequently (less than 15% of cases), strokes are 
caused by hemorrhage or cardiac arrest. In the USA, as in other 
industrialized countries, stroke rates, adjusted for age, declined over the last 
30 years (126). On average, in the USA strokes hit every 40 seconds and 
cause death every 4 minutes with an estimated death rate in 2007 of 41,6%. 
With the aging population these numbers may stabilize or increase over the 
next two decades. Among survivors, work capacity is compromised in 70% 
of patients, and 30% need assistance with self-care. From this point of view, 
the cost for stroke is a really massive problem. Changes in population 
demographics and overall risk of disease will place demands on health 
services for both acute stroke care and long-term care associated with more 
severe loss of function. New risk scores can risk-stratify patients presenting 
stroke and provide insights into the likely hood of long-term disability (127). 
In 2010 the estimated rate was 73.7 billion dollars for USA and projected to 
be 1.52 trillion dollars in 2050. This situation is a global mankind problem, 
and no racial or ethnic groups are spared. Developing industrialization of 
Asia and Africa is increasing unhealthy lifestyles, which promote stroke and 
other cardiovascular disease. As a result, the highest rates of stroke 
mortality and long-term disability occur in Asia, Russia, and Eastern Europe 
(128). Stroke is increasing rapidly in Eastern Europe and Central Asia 
compared with Western Europe and the United States (126). In China, rates 
of stroke and other cardiovascular disease are projected to increase 
dramatically due to combination of an aging population and the high 
prevalence of smoking and hypertension, for these reasons the estimated 
death rates are five to ten times higher than in USA (129). The types of 
stroke are also changing in rapidly developing Asian countries such as 
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China, with an increase in ischemic stroke and a decline in hemorrhagic 
stroke likely what seen in industrialized countries (130). Risk factor 
management is extremely important for the primary and secondary 
prevention of stroke in Asia as it is Western countries. In a meta-analysis of 
several Japanese studies of patients with non-cardiac sources of stroke, 
systolic and mean blood pressure were related to the risk of hemorrhagic 
and ischemic stroke and represent first targets for prevention programs 
(131). Ischemic stroke is a manifestation of atherosclerosis, a disease that 
affects all major arteries in the body. It is not surprising that recent studies in 
industrialized communities show fairly high rates of asymptomatic coronary 
disease in patients with stroke (132). 
For that matter gender difference in the pathology, recent research 
demonstrates that women are disproportionately affected by stroke. Indeed it 
is the third leading cause of death for women, compared to the fifth leading 
cause of death for men (133). In the United States, there are currently 26% 
more female stroke survivors than male and this disparity is expected to 
increase as the aging population continues to expand, by the fact that the life 
expectancy is longer for woman than for men (134). Women have a lower 
incidence of ischemic stroke than men across most age groups, but in the 
highest age group (85 years of age) women have higher stroke incidence 
(135). While social factors certainly play a significant role, men and women 
exhibit a wide variety of biological variances that may contribute to this 
disparity, including differences in genetics, hormonal factors and immune 
response. 
 
 
 
 
 
Part II                                                                                                              Introduction 
 
  
 71 
1.1.2. ORIGIN AND RISK FACTORS 
A stroke risk factor is a characteristic of an individual that increases the 
risk for stroke compared to someone without that characteristic (136). 
Several risk factors for stroke have been identified by epidemiological 
studies. Some of these can be modified through pharmacological or non-
pharmacological interventions and their identification is crucial to primary 
and secondary stroke prevention. Well documented modifiable risk factors 
for stroke are related to cardiovascular system such as arterial hypertension, 
some heart diseases, left ventricular hypertrophy, carotid stenosis, transient 
ischemic attack. Also metabolic conditions can play an important role like 
diabetes mellitus, hyperhomocysteinemia; not less important is lifestyle, and 
in this way is evident how cigarette smoking, alcohol abuse and limited 
physical activity have a fundamental role in stroke incidence. Other probable 
risk factors still not well documented so fare include some other heart 
diseases, plaques of the aortic arch; hormonal variations, such as use of oral 
contraceptives or hormonal replacement therapy. By the way also migraine, 
anti-phospholipid antibodies and hemostasis factors showed to be probable 
risk factors. For what that concern lifestyle, infections, drug use and air 
pollution, they have shown a correlation still not confirmed. Finally lipid 
metabolism plays a crucial role with dyslipidemia, metabolic syndrome and 
obesity. Hypercholesterolemia, the best documented modifiable risk factor 
for coronary artery disease, is incompletely defined. These risk factors often 
coexist, and they have been estimated to account for 60-80% of stroke risk 
in the general population (137). Some other risk factors cannot be 
modifiable; however they contribute to definition of risk classes, such as 
older age, male sex and Hispanic or Black race. Actually also a low birth 
weight is associated in several populations with the risk of stroke later in life 
(136). Family history of cerebrovascular diseases could be a makeable 
factor for the predisposition to stroke, although the role of a genetic condition 
in the pathogenesis is still unclear (138).  
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In clinical practice, total risk to occur in a stroke event is categorized in 
high, intermediate and low risk. For instance patients who have experienced 
a stroke are supposed to be at high risk because they are highly likely to 
have a further stroke in the next 10 years. However, some asymptomatic 
patients with multiple risk factors, particularly those with type 2 diabetes, 
may also be considered as high risk (conventionally more than 20%) for 
future cerebrovascular events in the next 10 years. Most people with only a 
single risk factor are at lower short-term risk. Nonetheless, even single risk 
factor if severe and sustained, can lead to premature cerebrovascular events 
and should not be ignored in clinical practice (139). A number of tools for 
estimating risk of coronary heart disease or other atherosclerotic diseases 
have been developed over the past 10 years, including risk score charts, risk 
assessment algorithms and computer software programs (138). 
The interaction of the various risk factors is not directly additive but 
more realistic a factorial event, and the risk to incur in death by a stroke 
attack increases with the number of factors (140). Certainly, modifications of 
life habits across wide populations are responsible for the emergence of 
most of these risk factors, and cultural modifications are common. These 
complications include increasing obesity and decreasing physical activity, 
conditions that are progressively much more important in these decades 
(138).  
Risk factors have significant effects on the structure and function of 
blood vessels and also on their own interface with circulating blood. Many 
elements detailed previously alter vascular structure by promoting 
atherosclerosis and the solidification of the vessels walls. In brains these 
morphological changes are often associated with marked alterations in 
cerebral blood flow regulation. As a consequence, aging, hypertension, 
diabetes, and hypercholesterolemia impair vital adaptive mechanisms and 
the brain is not more adequately perfused (141). The ability of the 
endothelium to regulate microvascular flow is compromised, while the 
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increase in blood flow evoked by neural activity is suppressed, resulting in a 
mismatch between the brain’s energy supply and demand (142).  
Many of these cardiovascular risk factors increase production of ROS 
and promote inflammation in systemic and cerebral blood vessels. As shown 
in figure 28 the predominant vascular sources of ROS are the superoxide-
producing enzyme NADPH oxidase, xanthine oxidase (XO), mitochondrial 
enzymes, and uncoupling of NOS, a state in which this enzyme generates 
superoxide instead of NO (143). 
 
Figure 28. Predominant sources of ROS in brain and blood vessels. The increase of Ca2+ 
activates the superoxide-producing enzyme NADPH oxidase (NOX) and induced protease 
activation that is responsible for the conversion of xanthine dehydrogenase (XDH) to XO. 
Mitochondria become depolarized by the Ca2+ overload producing large amount of superoxide 
 
 Many of the damaging effects of oxidative stress on blood vessels are 
related to the biological inactivation of NO, thus loss of its regulatory effects 
leads to vasoconstriction and a reduction of vascular responses dependent 
by NO. This condition has implications on the regulation of microvascular 
flow (144). On the other hand, NO inactivation promotes key steps in 
vascular inflammation, such as platelet aggregation and leukocyte adhesion 
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to endothelial cells (145). In addition, ROS can also promote directly 
inflammation by increasing BBB permeability through up-regulation of 
vascular endothelial growth factor (VEGF) and by inducing the expression of 
cytokines and pro-inflammatory genes by nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κb) activation (146). Considering that ROS 
may set the stage for inflammation, vascular inflammation, in turn, leads to 
ROS production, creating a vicious circle that enhances an increasing 
vascular damage.  
Thus, vascular inflammation and oxidative stress are major pathways 
through which risk factors enforce their damaging effects on blood vessels. 
However, it remains to be determined how individual risk factors trigger the 
activation of one or both of these processes. This is a critical question for 
targeting preventive strategies in patients with specific risk factors. 
Exacerbation of vascular inflammation and activation of the coagulation 
cascade are likely to play a role. For example, the added vascular 
dysfunction and blood clotting abnormalities could precipitate vascular 
occlusion or hemodynamic insufficiency. This view is supported by the fact 
that acute stroke often occurs in the setting of increased circulating 
leukocytes and elevated plasma markers of systemic inflammation and 
vascular activation, which also predict a poor outcome (147). 
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1.1.3. TYPICAL NEUROPATOLOGY OUTCOME 
Even though over the last two decades, advances have been made in 
diagnosis and treatment of acute stroke, the pathology is still a leading 
cause of death in developed countries. After an ischemic event 
complications include medical and neurological features. It is complicated 
define clearly which are the typical neuropathology outcomes after a stroke 
episode. Neurological complications are less frequent than medical 
complications but generally occur earlier in the course of stroke progression 
(148). 
Principal clinical features observed are chest and urinary infections 
predominantly because of the hospitalization. Beyond these consequences 
an important tendency toward increased diagnosis of depression is reported 
after stroke (148). For what that concern neurological outcomes they are 
estimated to be the major cause of death in the first days (149).  
The leading cause of death after stroke especially in the first week is 
brain edema. This complication occurs by the ionic imbalance due to energy 
depletion (150). It is possible to identify two types of edema after a stroke 
event, cytotoxic and vasogenic. The first one, not responsive to anti-
edematous treatments, is characterized by the translocation of interstitial 
water into the intracellular compartment and occurs in first stages, when the 
BBB is still intact (151). After that, when the BBB is already compromised, 
the second kind of edema will be recognized. Vasogenic edema is identified 
by fluid movement from vascular to extravascular spaces. This process 
leads to an expansion of brain volume that means an increasing intracranial 
pressure, herniation, and reasonably additional ischemic injures (152). This 
feature is like to be more important and devastating for young patient than 
older, probably because of the age-related brain tissue atrophy that seems 
to have a role in the protection from edema formation (153). 
Another important neurological outcome after ischemia is the 
hemorrhagic transformation of brain infarction. The main causes of 
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hemorrhagic conversion are the loss of microvascular integrity and 
disruption of neurovascular homeostasis (154). The mechanisms for the 
disruption are multifactorial, and these factors can interact with each other; 
they have been identified as treatment, inflammation, VGEF, NOS, and free 
radicals (151). Hemorrhagic transformation expands brain edema, leading to 
displacement and disruption of brain structures. The combination of these 
factors is associated with extremely high rates of mortality because 
increases intracranial pressure and induces apoptotic neuronal and glial cell 
death (155). This complication is more frequent in older people than in 
young patient owing to factors such as impaired rate of pharmacological 
treatment clearance and possible age-related microangiopathy (like cerebral 
amyloid angiopathy or hypertensive microangiopathy) (156). 
Seizures can occur soon after the onset of ischemic stroke or can be 
delayed. Early seizures are usually defined as those that occur within 1 or 2 
weeks after stroke and late seizures as those that occur after that. Although 
early seizures after stroke are thought to result from cellular biochemical 
dysfunction leading to electrically excitable tissue, late-onset seizures are 
thought to be caused by gliosis and the development of meningocerebral 
cicatrices (157). 
Another common problem in the acute stroke settings is delirium. 
Delirium is defined as an acute transient disturbance of consciousness and a 
change in cognition with fluctuating intensity (158). The cause of stroke 
related delirium is far to be clearly understood, but changes in 
neurotransmitter concentrations (e.g., acetylcholine and dopamine, 
serotonin, norepinephrine, and GABA), a non-specific reaction to stress, and 
activation of the hypothalamic–pituitary–adrenal axis might have a crucial 
role (159). 
Finally sleep disorders are frequent in the initial stages after stroke in 
the form of increased sleep needs (hypersomnia), excessive daytime 
sleepiness, or insomnia. Sleep-disordered breathing in patients presenting 
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with obstructive, central, or mixed apneas is common after stroke, occurring 
in about 50–72% of patients, and is both a risk factor and a consequence of 
stroke. The most common form of sleep-disordered breathing is obstructive 
sleep apnea, which is caused by cessation of nasal flow because of collapse 
of the upper airway (160). 
Ultimately, recent studies support that patients with a history of stroke 
are associated with higher risk of AD compared with non-stroke patients 
(12). The pathologic characteristics of AD might be accelerated by 
cerebrovascular familiar predisposition or disease. Atherothrombotic stroke, 
the most common type of stroke, often reflects more severe cerebral 
atherosclerosis. The atherosclerotic lesions might alter endothelial 
permeability of the BBB, allowing greater exposure of parenchyma to 
systemically circulating molecules, including oxidants, cytokines, or β-
amyloid protein. The presence of cerebrovascular injury, even if it does not 
cause measurable deficits itself, might cause increased cognitive 
dysfunctions in the presence of a concomitant degenerative process. In 
addition, if the strategic placement or a certain amount of brain tissue was 
injured by stroke, this might lessen the burden of AD pathologic changes 
required to produce symptoms of dementia. Association between stroke and 
AD has been reported in previous studies, but the literature on the opposite 
association (AD on stroke risk) is scarce (12). 
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1.1.4. CELL DEATH MECHANISMS IN CEREBRAL ISCHEMIA 
A cerebral stroke event is characterized by a rapid decrease in the 
cerebral blood flow. From the moment that often this episode is a focal 
condition, is possible to see, in the central core regions of the insult, an 
almost total arrest of the blood flow. This area evolves rapidly to death, but 
surrounding this core, in the penumbra area, flow levels may fall below 
functional boundary yet transiently lie above the threshold of cell death.  
The penumbra, a metastable zone, is considered the potentially 
recoverable tissue, because permits cell survival for a certain period of time 
(Fig. 29). This condition made penumbra the target for neuroprotective 
therapy (161).  
 
Figure 29. Penumbra and Core zone in the ischemic cerebral area. 
 
The most upstream consequence of cerebral ischemia fundamentally is 
an energetic problem. In the area of reduced blood supply, ATP 
consumption continues despite insufficient synthesis, causing an increase of 
total ATP levels and a development of lactate acidosis with concomitant loss 
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of ionic homeostasis in neurons. In a second moment, the ischemic cascade 
follows involving multimodal and multicell downstream mechanisms.  
The consistent loss of energy stores result in ionic imbalance, 
neurotransmitter release, and inhibition of reuptake. This is mostly important 
for the main excitotoxic neurotransmitter, glutamate. It binds to ionotropic 
receptors N-Methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic (AMPA), to promote the influx of calcium in cells. When 
that happens the ion overload, triggers phospholipases and proteases to 
degrade essential membranes and proteins. Glutamate receptors are also 
responsible for an excessive promotion of sodium and water influx in the 
cell, producing cell swelling, edema and a consequent reduction of 
extracellular space (162). Not less important a massive calcium influx 
activates catabolic processes mediated by proteases, lipases, and 
nucleases. Because of the increasing calcium, sodium, and ADP levels in 
ischemic cells, the result is an excessive stimulation of mitochondrial oxygen 
radical production, within other sources of free radicals production such as 
prostaglandin synthesis and degradation of hypoxanthine.  
ROS are directly responsible for lipid, protein, nucleic acid, and 
carbohydrate damage (163). From the moment that not only any 
corresponding up-regulation of antioxidant enzymes, such as superoxide 
dismutase (SOD) and catalase, but also other scavenging mechanisms are 
too slow to quenching ROS production, the effect of free radicals is 
especially toxic for cells. Thus, ischemic process and reperfusion activates a 
multimodal cascades will result in a complex mix of neuronal death 
comprising, necrosis, apoptosis, and autophagy. 
Necrosis is a frequent outcome of ischemia and reperfusion that is 
characterized by cell and organelle swelling with subsequent rupture of 
surface membranes and the release of intracellular contents. This event is 
responsible for the immunoinflammatory response and cytokine production 
(164). 
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After acute ischemic cerebrovascular event, neurodegeneration in the 
perinfarct area is gradual and dominated by apoptosis that has been 
reported to be associated with an increased expression of p53 (165). 
Analysis of single nucleotide polymorphisms (SNPs) in chromosomal DNA 
showed that the Arg72 variant of p53 had a higher ability to induce neuronal 
apoptosis than the Pro72 variant and it is able to increase the vulnerability of 
neurons to ischemia-induced apoptosis through the mitochondrial pathway. 
Indeed, the Arg72 variant translocates to mitochondria where it binds and 
inactivates Bcl-XL inducing cyt C release and caspase-9 activation (Fig. 30). 
Caspase-9 activates downstream caspases and, among these, caspase-6 
seems to be responsible for axonal degeneration and subsequent neuronal 
death. The time course of caspase-6 activation corresponds with axonal 
degeneration observed in human stroke as well as in other rodent models 
(166). Most importantly, the delayed time course of axonal caspase-6 
activation, occurring between 12 and 24h, makes it an attractive molecular 
target for neuroprotection (167).  
On the other hand, apoptosis may also be modulated by the 
transcription factor NF-kB during ischemia and reperfusion, because of 
limited oxygen availability is associated with its activation through a 
mechanism involving hypoxia-dependent inhibition of oxygen sensors (168). 
However, morphological evidence that ischemia causes classical apoptosis 
of neurons in the adult brain is less consistent. Outside of necrotic core of a 
typical brain infarct, there are neurons, in which condensation of chromatin is 
often an early result.  
In contrast, cytoplasmic blebbing and the formation of typical apoptotic 
bodies are unusual, and nuclear DNA degradation is often delayed until 
morphological changes of cell death are advanced (169). Although there are 
many reports of apoptotic death of neurons in models of ischemic stroke in 
adult animals, relatively few of those have been based on detection of the 
characteristic morphological features of apoptosis (170). 
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Figure 30. Apoptosis activation in stroke. Arg72 and Pro72 polymorphic variants can 
activate p53-downstream proapoptotic genes. Moreover, Arg72 increases the vulnerability of 
neurons to ischemia-induced apoptosis through the activation of the mitochondrial pathway: 
Arg72, but not Pro72, translocates to the mitochondria and directly binds to, and inactivates, 
Bcl-xL. This induces cyt C release, caspase-9 and -3 activation and finally neuronal apoptosis. 
 
For this reason it has been suggested that ‘caspase-mediated cell 
death’ is a more accurate description than ‘apoptosis’ of the programmed 
cell death that can result from ischemia in the adult brain, especially 
because post-ischemic neuronal death may involve a combination of 
apoptotic and necrotic processes (171). 
There is strong evidence supporting the idea that autophagy is an 
adaptive response to stress, such as nutrient deprivation, and the deletion of 
key autophagic genes accelerates rather than inhibits cell death (164). The 
hypoxia-inducible factor (HIF), a central mediator of hypoxic responses, also 
seems to regulate autophagy. The process of mitochondrial autophagy is 
induced by hypoxia and requires HIF-dependent expression of autophagic 
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genes, indicating a crucial role for HIF in the metabolic adaptation of hypoxic 
or ischemic tissues during conditions of limited oxygen. The first report of 
Nitatori and colleagues (171) demonstrated an increasing autophagy after 
cerebral ischemia, which showed that the increased lysosomes in neurons 
after transient global cerebral ischemia are mostly autolysosomes. Anyway, 
autophagy process is not always a protective outcome in cell life. In 2012 
Shi and colleagues demonstrated that physiological levels of autophagy 
promote survival, whereas insufficient or excessive levels of autophagy 
promote death. It is possible that prolonged oxygen deprivation/reperfusion 
determines an excessive autophagy response, switching its role from 
protective to deteriorative (172). Probably the time at which autophagy is 
induced determines its role. Autophagy could play a protective role in 
ischemic preconditioning but have a different effect once 
ischemia/reperfusion has occurred (173).  
In parallel with the molecular events briefly outlined here, another 
physiologic process called cortical spreading depression (CSD) has also 
been recently identified as a candidate target for stroke (161). CSD occurs 
when extracellular potassium exceeds a critical threshold; it consists in an 
intense depolarization of neuronal and glial membranes that slowly 
propagated by way of gray matter contiguity. The process is characterized 
by a near complete breakdown of ion gradients and near complete sustained 
depolarization that is express by an extreme shunt of neuronal membrane 
resistance with a consequent loss of electrical activity, neuronal swelling, 
and distortion of dendritic spines (174). Under physiological conditions, CSD 
is associated with a major cerebral blood flow rise in an attempt to match the 
increased metabolic demand. Under pathological conditions such as 
ischemia, can be observed an inverse hemodynamic response characterized 
by a blood flow reduction that increment that adverse event (175). In 
ischemia, these waves of CSD originating in the peri-infarct area can invade 
repeatedly the peri-ischemic tissue, adding a major metabolic demand on 
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penumbra, and at term, the spreading depolarization expands the volume of 
infarction (174) (Fig. 31).  
This overview is useful to understand how is complicate define a 
specific way not only for the intervention but also in the prevention and in the 
definition of conditions necessary for a better outcome after an ischemic 
stroke event. 
 
 
Figure 31. Cortical Spreading Depression (CSD). The vicious cycle underlying spreading 
ischemia. The decline in oxidative substrate supply while energy demand is increased, determines 
fall of tissue ATP with reduced sodium pump activity. There is also failure of neuronal 
repolarization and, therefore, continued release of vasoconstrictors, which maintains the perfusion 
deficit while the perfusion deficit maintains the depolarization.  
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1.2. ANIMAL MODELS 
Animal models of stroke can contribute to understand etiology of 
different subtypes of stroke so as develop a better prevention and treatment 
strategies. We have to consider that for some pathology many animal 
models are not able to represent the whole disease process but aim to 
enable detailed study of specific aspects. Animal models are also useful in 
testing promising therapeutics interventions, both pharmacological and non-
pharmacological. Most animal models of stroke are rodents, rabbit, pigs, 
dogs, and in few cases primates. These models can be divided in two types: 
models in which stroke are induced through artificial ways and animals in 
which stroke occur spontaneously (176). 
The choice of the model depends on the research question. Acute 
stroke presents inherently a high variable clinical condition that may be 
eliminated by animal models, but some of them can fully mimic the 
complexity of the stroke event. Before choosing an appropriate model there 
are few important key points to establish. First, consider for which types of 
human stroke the treatment under investigation may be relevant, then 
lesions procedures must be reproducible and minimal invasive. Not less 
important in the choice of the model used is if it allows assessment of a 
relevant, functional, neurobehavioral outcome (177). 
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1.2.1. INDUCED STROKE MODELS 
Models of global ischemia 
Acute models of global ischemia may mimic the cerebral damage that 
occurs after cardiac arrest, while chronic cerebral hypoperfusion models are 
representative of subcortical white matter damage similar to what is thought 
to be due to cerebral small vessels disease. Often the damage is induced in 
rodents by permanent occlusion of both vertebral arteries and or transient 
ligation of two common carotid arteries. These methods are responsible of 
an extensive bilateral forebrain injury (178). In order to produce mainly white 
matter lesions, it is possible to use a chronic global hypoperfusion model 
either by ligation of common carotid arteries or stenosis using external 
microcoils (179) (Tab. II). 
Table II. Rodent models of global ischemia 
MODEL ADVANTAGES DISADVANTAGES 
ACUTE 
Four-vessel occlusion Reversible forebrain ischemia, may be induced in awake animals Two-stage surgery 
Two-vessel occlusion Reversible forebrain ischemia, One-
stage surgery 
Necessity of systemic 
hypotension 
Asphyxia cardiac arrest Whole brain ischemia Intensive postsurgery care 
CHRONIC 
Bilateral common 
carotid artery ligation 
Produces white matter changes similar 
to leukoaraiosis High death rate 
Bilateral common 
carotid artery stenosis 
Produced milder reduction in cerebral 
blood flow 
Take long time to develop 
lesions 
Asphyxia cardiac arrest Whole brain ischemia Intensive postsurgery care 
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Models of Middle Cerebral Artery occlusion (MCAo) 
Models of MCAo were developed to mimic the consequence of the 
most frequent ischemic stroke. This model has been reported to induce long-
term sensorimotor and cognitive deficits as well as impairments of postural 
and sensory reflexes (180). In order to produce vessel occlusion 
endovascular or surgical procedures are commonly used. In this way it is 
possible to perform a permanent or transient event. A model of transient 
MCAo permits to investigate either brain injury related to the ischemic event 
and the consequences of reperfusion (181). Another way to induce MCA is 
thromboembolic occlusion that is commonly obtained by injection of blood 
clots. This model permits to investigate the potential of antithrombotic drugs 
(182). It is possible to induce a thromboembolic stroke also by injection of 
sodium dodecyl sulfate (SDS) detergent or by deliver of photoactivated 
thrombogenic agents (183, 184) (Tab. III). 
Table III. Rodent models of focal ischemia 
MODEL ADVANTAGES DISADVANTAGES 
Endovascular MCAO Most common method used for permanent or transient stroke Risk of vessel rupture 
Surgical MCAO Control of occlusion site, less 
variability Necessity of craniotomy 
Thromboembolic MCAO Mimics most common cause of ischemic stroke in human Higher variability  
Phototrombosis Less invasive procedures Less relevant for human 
condition 
Intracarotid injection of 
SDS detergent Selective perforating artery occlusion 
Unpredictable distribution 
of infacts 
 
Models of induced sub-arachnoid hemorrhage (SAH)  
Models of SAH present intracranical bleeds in the space between the 
arachnoid membrane and the pia mater, frequently by endovascular 
perforation or by injection of blood. The second one allows a close control of 
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the hemorrhage volume, but the first one describes in a better way what 
happen in human pathology (185) (Tab. IV). 
Table IV. Rodents model of sub-arachnoid hemorrhage 
MODEL ADVANTAGES DISADVANTAGES 
Endovascular 
perforation 
Reproduce aneurysmal clinical condition in 
humans High mortality rate 
Intracisternal blood 
injection 
Severity may be controlled by blood 
quantity and number of injections 
Nonphysiological blood 
distribution 
 
Models of induced intracerebral hemorrhage  
The most used model to investigate intracerebral hemorrhage consists 
in the injection of bacterial collagenase or blood in a specific brain area by a 
stereotaxic probe. From the moment that collagenase disrupts the basal 
lamina of vessels causing a spontaneous bleeding that permits to investigate 
hemostatic aspects of the pathological event (186) (Tab. V).  
Table V. Rodents models of intracerebral hemorrhage 
MODEL ADVANTAGES DISADVANTAGES 
Intracerebral 
injection of bacterial 
collagenase 
Mimics humans condition 
Bacterial collagenase may 
induce inflammatory 
response 
 Intracerebral blood 
injection Without confounding inflammation 
Neurofunctional deficits 
resolve more rapidly 
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1.2.2. TRANSGENIC MOUSE MODELS 
A number of rare forms of stroke occur in humans as a result of single 
gene disorders (187). This includes conditions responsible of specific 
vasculopathies that may give lacunar ischemic strokes. The most common is 
cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leuco-encephalopathy (CADASIL), resulting from mutations in the Notch3 
gene. In this regard, several Notch3 mutant mouse models have been 
developed, which reproduce the features of human CADASIL vascular 
pathology accompanied by progressive white matter damage, without 
infarcts (188). These and other transgenic mouse models are a developing 
study area because permit the investigation either into the disease 
mechanism of rare forms and new treatments for the uncommon monogenic 
subtypes of stroke. 
It is important underlie the presence of significant animal models of 
stroke that permit to investigate single mechanism of interest, such as 
hypertension or inflammation. In this context it is possible to study the 
involvement of a single component in the outcome of the pathology that 
allows identifying a probable strategy for neuroprotection. 
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1.3. STRATEGIES OF NEUROPROTECTION 
Neuroprotection defines any strategy with the aim of antagonizing 
molecular and cellular events responsible for the ischemic damage, allowing 
neurons to survive when cerebral blood flow is reduced and to stabilize 
penumbra area (189). One approach to manage stroke injury is known as 
preconditioning. Preconditioning is a well-defined phenomenon by which is 
possible to give protection and tolerance by a small harmful stimulus before 
a damaging event (190). Preconditioning induces a transient window of 
protection that requires gene activation and new protein synthesis (191). If 
stroke occurs during this window after preconditioning, the response is 
reprogrammed to produce new signaling cascades to promote protection 
and resist injury. Preconditioning can be viewed in three sequential phases: 
a priming phase that sets up protection, a refractive phase when the system 
is resistant to injury, and a neuroprotective phase that is characterized by a 
reprogrammed response to stroke that reduces injury (190). Obviously the 
preconditioning process results to be useful in research studies because 
allow to identify which mechanism may be modulate to target an efficient 
alternative neuroprotective therapy. On the other hand, for what that concern 
clinical practice, application of preconditioning phenomenon is not frequently 
helpful.  
We have already explained how not only the ischemic process, but also 
the reperfusion phase is fundamental in the production of ROS and the 
subsequent cellular death cascade. In this instance appear clear that a 
neuroprotective approach focused on the antioxidant responses would be 
the powerful way to prevent, slow down and control consequences of a 
cerebral stroke and reperfusion injuries.  
Because of the complexity of various mechanisms responsible of the 
tissue damage after stroke, the best approach has to suppress many of 
them, alone or by a combination. 
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The production of ROS and other free radicals is a consequence of 
inflammation but also of excitotoxicity (192). These molecules, such as •OH, 
O22- and peroxynitrite are highly reactive species, able to damage multiple 
cellular components, leading to cell death. One way of reducing oxidative 
stress is to decrease the production of free radicals. For instance, although 
NO is a normal signaling molecule in the body and has beneficial effect in 
stroke, larger amounts resulting from increased activity of the induced nitric 
oxide synthase (iNOS) can lead to aberrant signaling or react with 
superoxide to produce peroxynitrite. At this purpose the administration of an 
antioxidant, able to decrease iNOS production and increases expression of 
endothelial nitric oxide synthase (eNOS), may be efficient for the reduction 
of histopathological changes. Another source of ROS is the NADPH 
oxidases, so inhibitors of these enzymes could be beneficial as the induction 
of SOD and GPx (193). In this context it is important to remember that many 
exogenous compounds, natural or synthesis origin may play a crucial role to 
reduce ROS production and to contain damage related. 
In a stroke event, disruption of the BBB is commonly associated with 
the action of two matrix metalloproteinases, MMP-2 and -9. These 
metalloproteinases are constitutively expressed at low levels, however 
ischemia increases them expression and activity. Other factors are involved 
in BBB permeability after stroke, including the extent of tight junction 
formation between endothelial cells and the effects of treatment with tissue 
plasminogen activator. The activity of MMPs is regulated endogenously by 
the tissue inhibitor of matrix metalloproteinase, to this end treatments that 
stimulate it may show a significant neuroprotective role against brain 
damage induced by stroke (193). 
During stroke, depletion of neuronal oxygen and energy reserves leads 
to the release of toxic amount of the neurotransmitter glutamate into the 
extracellular space. Glutamate excitotoxicity plays a significant role in the 
pathology, for this reason a valuable key for neuroprotection is to diminish 
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glutamate release or manage the action of glutamate receptors in the brain 
(125). 
We have already explained that apoptotic process is fundamental in the 
evolution of tissue damage after stroke. The crucial role of apoptosis is also 
related to the fact that this cell death pathway is characteristic of penumbra 
area, the part of lesion where is possible to reverse neuronal loss 
advancement. Apoptosis may be induced by mitochondrial pathway or 
caspase dependent pathway. For this reason reduction of activated 
caspase-3 levels may be the goal for neuroprotective treatments (193). 
Autophagy appears to have a dual role in the response to cellular 
damage, absorbing damaged components as a protective measure in some 
cells and serving as a mechanism of cell death in others (194). Induction of 
autophagy prevents cell death by apoptosis and in this context is considered 
to be beneficial. Alternatively, the inhibition of autophagy can also be 
considered neuroprotective. In pMCAO rats, ischemic postconditioning 
inhibited the induction of autophagy and reduced infarct size and edema 
(195). It is hopeful that further research will determine if the effect of 
autophagy in stroke would be beneficial or harmful. 
Neuroprotection will be the fundamental key point for a good outcome 
after a stroke event, all mechanisms listed before are considered potential 
target for a powerful neuroprotective therapy. 
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1.3.1. INFLAMMATION INVOLVMENT IN ISCHEMIA PROCESS 
Another important factor involved in the ischemia process is 
neuroinflammation. Inflammation is a double faced mechanism, on one hand 
it determines an increased cerebral blood flow to the affected area and the 
removal of damaged tissue by phagocytic cells; but on the other hand 
secretory factors released by cytokines and chemokines may reach toxic 
levels, besides the incremented production of ROS and the consequent 
destruction of the BBB (196). 
In an intact brain, the trafficking of cellular and molecular components 
from peripheral circulation is regulated by the BBB. In this condition, immune 
response in the CNS is regulated by resident microglia. Following a brain 
insult, the tight junctions between endothelial cells become permeable, 
allowing peripheral immune cells to infiltrate brain parenchyma (197). Acute 
inflammation after stroke originates from activation of resident immune cells, 
the microglia, followed by infiltration of peripheral inflammatory cells (198). 
Microglia exists in two different states, the M1 and the M2. On activation 
microglia takes on the M1 phenotype and secretes various proinflammatory 
molecules including interleukin (IL)-1β, TNF-α and ROS. When microglia 
turns on the M2 phenotype, secretes the anti-inflammatory molecules such 
as IL-10 (199). Macrophages, which reside in the perivascular space, are a 
large driving force behind infiltration of peripheral immune cells into the brain 
parenchyma (200). Macrophages exist in multiple states that are 
phenotypically and functionally distinct, such as microglia phenotypes, M1 
and M2. After macrophage and neutrophil infiltration, lymphocytes begin to 
infiltrate the brain as well. Under normal conditions, T cells are not able to 
migrate through the BBB and enter the brain. However, after injury, activated 
CD4+ and CD8+ T cells can enter in the brain (201). In addition, there are 
CNS-specific T cells that promotes leukocyte passage into the CNS after 
injury (199). Approximately 15% of these T cells are CD4+ TH1 cells, which 
stimulate cytotoxic CD8+ T cells, and secrete a membrane-permeabilizing 
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molecule. Furthermore they induce apoptosis through caspase activation or 
by activation of the Fas ligand pathway. In addition to TH1 cells, TH2 cells 
secrete numerous interleukins (IL-4, 5, 9, 10, and 13) that are important for 
activation and recruitment of cells, namely B cells, involved in the humoral 
immune response (197).  
ROS and inflammatory mediators cause endothelial cell and leukocyte 
expression of adhesion molecules, promoting the adhesion and migration of 
circulating leukocytes that leads to a rapid inflammatory state at the site of 
injury. Furthermore these leukocytes in turn release inflammatory cytokines 
that lead to tissue damage in the core and the ischemic penumbra (197) 
(Fig. 32).  
Inflammatory response has a crucial role in the tissue damage of a 
stroke event. TNF-α interacts with two receptors, R1 and R2, that mediate 
death signals by the Fas associated death domain (FADD) and inflammation 
through the NF-κB, respectively. On the other hand, the interleukins are 
another important set of molecules in the process of inflammation. IL-1 is 
proinflammatory, and IL-6 has both pro- and anti-inflammatory effects (202).  
As one of the early initiators of inflammation after stroke, TNFα is an 
excellent target for neuroprotective treatments. Activation of NF-κB by TNFα 
initiates a signaling cascade that regulates a number of inflammatory 
processes, making it a good point of intervention. The various signaling 
cascades induced by stroke lead to the activation and recruitment of 
inflammatory cells to the site of injury. 
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Figure 32. Inflammatory cascade. Cerebral ischemia leads to an initial cell necrosis and 
generation of ROS and proinflammatory molecules like IL-1β and TNF-α from injured neurons 
as well as inducing BBB dysfunction with loosening tight junctions between endothelial cells. 
This causes extravasation of circulating leukocytes into the brain parenchyma. When in the 
brain, leukocytes and activated microglia generate a variety of proinflammatory molecules and 
continue to generate ROS. These events lead to secondary brain injury, increased 
inflammation, and ultimately cell death. 
 
In the early stages of stroke, prior to the infiltration of neutrophils and 
macrophages from other locations, resident microglia is the primary 
inflammatory cells in the brain. Microglia continues to be involved well into 
long term recovery and it has been observed 28 days following stroke in 
MCAo rats (202). Although microglia serves a beneficial purpose by 
removing dead tissue, it also releases secretory factors that can accumulate 
to toxic levels, particularly in cases of excess activation such as stroke. The 
processes involved in inflammation may not only directly contribute to brain 
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damage following stroke but may also activate secondary mechanisms that 
lead to further damage. The activity of large numbers of inflammatory cells in 
the affected area, combined with low oxygen and ATP levels, leads to the 
formation of ROS and the onset of oxidative stress (193). 
Neuroinflammation after ischemic stroke is, for the most part, a self-
limiting event. Resolution of inflammation in the brain seems to be an active 
process in which inflammatory mediators are suppressed by regulatory 
mechanisms (193).  Furthermore, resolution of inflammation in the brain, 
involves clearing of dead and dying cells primarily by the phagocytic activity 
of activated microglia with the help from infiltrating macrophages as well as 
production of antiinflammatory, proregenerative signaling molecules which 
suppress inflammation and exert neuroprotective effects on the surviving 
cells. In the chronic phase of stroke, there is little contribution from either 
resident or peripheral immune cells; however, there is still an increase in the 
number of microglia that help in brain repair by clearing of dead and dying 
cells (192).  By understanding how inflammation increases the susceptibility 
toward premature CSN death, we can better design therapies to promote 
brain repair (193). 
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1.3.2. THE ROLE OF CD36 RECEPTOR IN INFLAMMATORY 
RESPONSE 
CD36 is a class B scavenger receptor that regulates physiological and 
pathological functions. This receptor is an 88 kDa glycoprotein that consists 
of two transmembrane domains, a large extracellular domain, and two short 
cytoplasmatic tails. Extracellular domain includes a hydrophobic region that 
may be buried within the plasma membrane, a proline-cysteine rich domain 
and ten potential N-linked glycosylation sites (203) (Fig. 33).  
 
 
 
 
 
 
 
 
 
 CD36 is expressed in many types of cells, from microvascular 
endothelial cells to microglia, macrophages, platelets, and adipocytes. For 
this reason this receptor is involved in numerous processes including 
inflammatory response. It is important to underlie that activation of CD36 
receptor is involved in many stroke risk factors, like hypertension, 
dyslipidemia and diabetes. This consideration makes the receptor of interest 
an important key point in neuroprotection strategy not only in stroke 
pathology but also in neurodegenerative diseases where BBB integrity and 
cerebrovascular abnormalities have a fundamental role, such as AD and 
atherosclerosis. 
Figure 33. Structure of CD36 receptor 
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As the most primordial function in the organism, innate immunity serves 
to recognize modified or oxidized phosphatidylcholine/serine of apoptotic 
cells (204). Triggered by tissue damage the innate immune system mediates 
inflammatory responses through a family of pattern recognition receptors. 
The receptors include toll-like receptors (TLRs) and CD36 which may 
recognize endogenous danger signals from damaged tissues (205). The 
pathogenic roles of CD36 and TLR2 in cerebral ischemia have been 
independently reported. CD36 expression increases in the post-ischemic 
brain, and CD36-knockout mice present a profound attenuation in the 
molecular and cellular inflammatory response induced by focal cerebral 
ischemia (206). Similarly, TLR2 expression is increased during ischemia and 
its deletion results in reduced ischemic injury (207). The closely shared 
function and physical association between CD36 and TLRs suggest that 
CD36 is involved in innate immune responses following cerebral ischemia. 
Targeting CD36 in an attempt to attenuate innate immune responses under 
pathological conditions may be a potential strategy for stroke therapy. Of 
particular note is that clearance of apoptotic cell bodies by phagocytosis, an 
essential function of scavenger receptors, may be an important process for 
tissue remodeling after injury (208). 
In particular, CD36 recognizes pathogen-associated molecular patterns 
and induces an inflammatory response through activation of NF-κB (209). In 
cerebral ischemia, CD36 mediates free radical generation and contributes to 
tissue injury in the postischemic brain (210).  The pro-inflammatory 
responses activated through interaction between CD36/CD36 complex and 
ligands are associated with generation of free radicals, cytokines, 
chemokines and foam cells, making this as an integral part of many 
pathological processes. In conclusion, neuroprotective strategies may be 
aimed at attenuating injury-induced inflammation by targeting CD36. 
 
Part II                                                                                                       Aim of the study 
 
 
 
 
98 
2. AIM OF THE STUDY 
 
Stroke is the third leading cause of death worldwide and the main 
cause of permanent adult disablement in industrialized countries (124).  
In USA strokes hit every 40 seconds and cause death every 4 minutes. 
Among survivors, the capacity of work is compromised in 70% of patients 
and 30% of them need assistance with self-care. Clearly appears how the 
stroke pathology is a really massive and economic problem worldwide (127). 
Strategies of interventions are aimed to restore cerebral blood flow, but 
there are no efficient therapies for the damage induced in tissues hit by the 
cerebral ischemia or by the reperfusion phase. 
For what that concern prevention of the disease, this pathology may be 
directed from many different risk factors, principally related to cardiovascular 
pathologies thus, the most efficient way to reduce the incidence is their 
modulation, and the education on a healthier life style.  For this reason, 
patients considerate at risk are treated with antihypertensive drugs or 
statins. 
    The role of neuroinflammation is considered more and more 
important in the outcome of stroke. Neuroinflammation is involved in 
neurodegenerative diseases, both chronic and acute, and this underlines its 
crucial role and a connection point among various pathologies affecting 
CNS. 
CD36 is a class B scavenger receptor that regulates physiological and 
pathological functions. For this reason, it is expressed in many types of cells, 
making the receptor involved in numerous stroke risk factors, where the 
inflammatory response shows a crucial role. 
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The aim of this work was to elucidate the potential neuroprotective role 
of a negative modulation of CD36 receptor, in a long term study, after MCAo. 
For this purpose, we used an integrated approach of behavioral tests, 
motor and cognitive, and immunohistochemistry evaluation. 
For the behavioral analysis we have used an extended variety of motor 
tests to evaluate functional, strength, balance, coordination and the 
extension of the lesion. This was possible by Modified Bederson test, 
Hanging wire test, Pole test, Corner test and Sticky tape test. For what that 
concern cognitive evaluation, we investigated if the declarative and non-
declarative memories were compromised through Novel Object recognition 
test and the Y-maze test from 3 weeks after stroke.       
 Finally, after the sacrifice, we utilized immunohistochemistry in 
fluorescence to evaluate the extension of ischemic damage, microglia and 
astrocyte activation, neurogenesis and angiogenesis processes.  
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3. MATERIALS AND METHODS 
 
3.1. ANIMALS 
Male mice C57BL/6JOIaHsd (Jackson Laboratories, USA) and 
CD36-/- (8 weeks old, 20 g body weight at the beginning of the 
experiment) were housed 5 for cage under 12 h light/12 h dark cycle 
(lights on from 6.00 a.m. to 6.00 p.m.) with free access to food and water 
in a temperature (22±2°C) and humidity (60%) controlled room. 
Experimental procedures were carried out in the light cycle (from 9.00 
a.m. to 5.00 p.m.) including control groups in each test performed.  In 
particular we used four experimental groups; wild type and CD36-
knockout operated and sham, both wild type and CD36-knockout. During 
six weeks after the lesion, once a week, we have assessed the extent of 
the lesion using several motor e cognitive tests. In order to acclimatize 
animals at the new environment, mice were moved in the behavioral room 
for at least 1 hour before starting the tests. At the end of behavioral 
analysis, mice were sacrificed by perfusion to perform 
immunohistochemistry. 
3.1.1. TRANSIENT OCCLUSION OF THE MIDDLE CEREBRAL 
ARTERY 
Animals were anesthetized using 4% isoflurane in oxygen, and 
anesthesia was maintained with 1.5-2% isoflurane in an oxygen/room air 
mix. Mice are kept at 37±0.5°C during the surgical procedure using a 
heated surgical surface. Using instant krazy glue and accelerator, the 
Doppler fiberoptic probe is attached to the parietal bone 2 mm posterior 
and 5 mm lateral to bregma. The fiberoptic probe is then connected to 
laser Doppler flowmeter and cortical perfusion flow recorded. At this 
position, was detected a reduction >85% in cortical cerebral blood flow 
Part II                                                                                      Materials and Methods 
 
 
101 
upon occlusion of the middle cerebral artery (MCAo) on the right side, 
resulting in a reproducible cerebral infarct. Ischemic lesion was inducted 
by the introduction of an intraluminal filament to occlude MCA for 30 
minutes (Fig. 34).  
 
Figure 34. Intraluminal filament MCAO. The filament is inserted between the two external 
carotid artery (ECA) 6-0 suture knots, and advanced along the internal carotid artery (ICA) 
until it reaches the origin of the MCA. 
After 30 minutes, the filament is retracted and an 80% recovery of 
cerebral blood flow must be observed in reperfusion that has to be 30 
minutes long. After the surgery animals were maintained in a temperature 
controlled cage until it regains complete consciousness (211). 
Motor behavioral assessment was performed by day 4 after the 
surgery and then once a week for six weeks. Cognitive evaluation was 
performed by the third week until the sacrifice. 
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3.1.2. TEMPERATURE 
The temperature was measured every day of the behavioral test to 
verify the condition of health after the induced cerebral ischemia. 
3.1.3. WEIGHT 
Animals were weight every day of the test to evaluate the condition 
of health and the percentage loss of weight. 
3.1.4. MODIFIED BEDERSON TEST 
Modified Bederson test allows to defining neurological assessment 
after MCAo surgery. Mice were scored from 0 to 4 according with the 
criteria showed in table VI (212): 
Table VI. Modified Bederson test scoring 
0 normal motor function 
1 
flexion of the torso and forelimb contralateral to MCAo when mouse is suspended 
by tail 
2 circling to the side contralateral to MCAo, when mouse is left on a flat surface 
3 leaning to the contralateral side at rest 
4 no spontaneous motor function 
 
3.1.5. HANGING - WIRE TEST 
Hanging-wire test was performed to evaluate forepaw strength. 
Animals are made to grasp, using their forepaws, the middle of a wire that 
is about 30 cm long and suspended at 50 cm above a soft surface. To 
prevent that mice could reach the pole that suspends the wire, poles are 
covered with a white paper (Fig. 35). 
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METHOD 
Two days before the surgery, mice started the training for two days. 
The first day of habituation to the tool is made through positioning animals 
on the wire just one time. The day after each mouse is collocated on the 
wire for one minute. If the animal can not stay on until the end of the 
minute, it is placed again until the end of the time. The day of the test, 
animals performed three trials with a cut off at one minute. 
Values were expressed as mean of three trials for each experimental 
group. 
 
Figure 35. Hanging wire test. Mice were left on the wire allowed to use only forepaws. 
 
3.1.6. STICKY TAPE TEST 
Sticky tape test was performed to evaluate sensitivity to perceive 
unknown objects and the ability to control faint movements. Briefly, the 
test consists in the evaluation of the time that animals need to remove 
from forepaws two little tapes earlier applied (Fig. 36). In this way it is 
possible toestablish not only the time to remove the tape, but also 
differences in the perception between ipsilateral and contralateral sides. 
Furthermore latency in the reaction from the time of the first contact with 
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the tape and the moment of removal can be an indication for the control of 
faint movements. 
METHOD 
The day before the surgery animals are trained in order to exclude 
mice with a side preference. Tapes of two different colors having 
dimension of 4 mm of length and 3 mm of height are prepared. Animals 
are located in an empty cage for one minute for the habituation at the new 
environment. Then a little piece of tape is applied on the forepaws, with 
attention to use pieces of the same dimensions and in the same position 
on each paw. After that, mice are left in the cage and times needed to 
touch for the first time and remove tapes on the right and left are 
recorded. The training consists in five trials or less, if mice are able to 
carry out the task in fewer than 20 seconds. The day of the test animals 
carried out one trial with a cut off at 3 minutes. 
Values were expressed as mean of the time in seconds and as 
relation between contralateral and ipsilateral sides. 
 
Figure 36. Sticky tape test. Two small pieces of colored tape with same dimensions were 
attached to the forepaws using the same pressure.  
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3.1.7. CORNER TEST 
Corner test was performed to evaluate sensory motor integration. 
Briefly, animals were placed between two boards angled at 30° with a 
small opening along the joint between those to encourage entry into the 
corner (Fig. 37). As the mouse enters the corner, both sides of the 
vibrissae are stimulated causing the mouse to rear on its hindlimbs and 
turn to the opposite side.  Normal mice not subject at ischemia have on 
average a 50% chance of turning to each side. However, mice subjected 
to cerebral ischemia have a >50% chance of turning to the right. 
METHODS 
A total of ten trials are performed with a cut off at 10 minutes. The 
direction that the mouse turns is recorded and the total percentage turns 
in the right (ipsilateral at the lesion) direction is calculated.  
Values are expressed as percentage of the ipsilateral rotation on the 
total number of turns. 
 
 
 
 
 
 
 
 
 
Figure 37. Corner test. When mouse entered in the corner it can fell with the vibrissae the 
two boards and turned on the right (ipsilateral) or left (contralateral) side. 
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3.1.8. POLE TEST 
The Pole test was first used to study motor involvement in PD. The 
test allows evaluating coordination and the balance of mice. Briefly mice 
were located on a pole with a diameter of about 1 cm and height 50 cm. 
The pole may be made of wood or any material that present a rough 
surface to allow animals walk over it. Mice were placed on the top of the 
pole facing up. The test consists in the evaluation of the time needed by 
the animal to turn around itself (time turning), and the time to reach the 
floor (time descending) (Fig. 38). 
METHODS 
Two days before the surgery, mice start the training for two days. 
The first day animals were placed on the pole facing down for five trials. 
Once the mice reach the floor, they are left to explore the environment for 
one minute. The day after, animals were located on the pole again, but 
this time, facing up. The time to turn around and the time to reach the floor 
are recorded for five trials, or less if animals took fewer than 10 seconds 
to carry out the task. The day of the test animals are placed on the pole 
facing up one time with a cut off at 1 minute. 
Values were expressed as time in seconds related to the best time 
reach in the training session. 
 
Figure 38. Pole test. Mice were located on the pole facing up, the task consists in turning 
around to be facing down and descending the pole to reach the floor. 
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3.1.9. NOVEL OBJECT RECOGNITION TEST 
The Novel Object Recognition test was carried out to evaluate the 
involvement of subcortical structures responsible of the construction of the 
declarative memory after MCAo (Fig. 39). 
METHODS 
The day before the test animals were trained for the habituation at 
the new environment. Mice were placed in an empty clear box of 
50x30x30 cm dimensions and left to explore the environment for ten 
minutes. The day of the test, each mouse was submitted for the training 
session. Animals were located in the box for five minutes with two similar 
objects in color and shape. After a retention time of 30 minutes, mice were 
placed again in the box for five minutes, but this time with one of the two 
object was replaced by one completely different in color and shape. The 
experiment was recorded by video camera located over the box. In order 
to evaluate the time spent in the exploration of each objects, registrations 
obtained were analyzed by Any-Maze program. 
Values were expressed as the percentage of time spent in the 
exploration of the new object related with the total time spent to explore 
both objects. 
 
Figure .39. Novel Object Recognition test. After a training phase of five minutes with two 
similar objects, mice are placed in the box with two different objects for five minutes. 
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3.1.10. Y-MAZE TEST 
Y-Maze test was carried out to evaluate the involvement of 
subcortical structures responsible of the construction of the non-
declarative memory after MCAo (Fig. 40). 
METHODS 
The maze utilized for the test presented three similar arms with an 
angle of 120° between each other. Animals were always located in the 
same arm of the maze. Mice were submitted at a training session of five 
minutes with one arm of the maze closed by a door. After 30 minutes of 
retention animals were placed again in the maze for five minutes, but 
allowed to explore all arms of the apparatus.  
Values were expressed as percentage of the time spent in the 
exploration of the new arm related with the time spent in the exploration of 
all three arms. 
 
Figure 40. Y-Maze test. After a training phase of five minutes with one arm closed, animals 
were left to explore freely the maze for five minutes. 
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3.1.11. SACRIFICE AND TISSUE PREPARATION 
Six weeks after the surgery, when behavioral analysis was 
completed, mice were deeply anesthetized and sacrificed by perfusion. 
First, animals were perfused with about 40 mL of PBS 1x/1 kU sodium 
heparin, and then with about 40 mL di PFA 4% in PBS 1x. After the 
perfusion the brain was collected and post-fixed overnight in PFA 4% in 
PBS 1x at 4°C. The day after the solution with PFA was substituted with a 
30% sucrose solution at 4°C to allow cryoconservation of tissues. The 
brains were conserved in sucrose solution for two days, until they could 
reach the bottom of the vial. Finally brains were frozen in dry ice and 
conserved at -80°C until tissue preparation. 
Brains were dissected with a microtome, this instrument allows to 
dissect frozen tissue, but also to conserve slices collected in free-floating. 
This choice was made because the friability of the ischemic tissue didn’t 
allow vibratome cutting, and also because the free-floating permit to 
obtain a better staining. Sections were collected between coordinates AP 
= 1.40 and AP = -0.45. For every four collected, five were discharge and 
then conserved at -20°C in Storage Solution (30% Sucrose, 30% ethylene 
glycol in PBS 0.1%). 
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3.2. IMMUNOISTOCHEMISTRY 
Slices for immunofluorances staining were choose and then colored in 
co-staining at 1:200. Different stainings were performed to assess 
neuroregeneration, neuroinflammation and vasogenesis. 
• PCNA + NeuN 
• DCX + PCNA 
• Glut-1 + PCNA 
• Iba1 + GFAP 
(PCNA Proliferating cell nuclear antigen, Ms Mab IgG2a, Cell Signalling 
Technology, Beverly, MA, USA) 
(NeuN Neuronal Nuclei, Ms Mab IgG1, Millipore, Billerica, MA, USA) 
(DCX Doublecourtin (N-19), Goat, Santa Cruz, CA, USA) 
(Anti-Glut1 Glucose Transporter-1, Calbiochem, USA) 
(Anti-Iba1, Rabbit, Wako Chemicals, Richmond, VA, USA) 
(GFAP, Monoclonal Anti Glial Fibrillary Acidic Protein, Sigma, St Louis (MO), 
USA) 
Secondary antibodies were used at concentration of 1:100 because 
conserved in 50% glycerol with the following combination, respectively: 
• FITC, Goat anti-Mouse IgG, Fcy Subclass 2a specific + Cy3, Goat 
anti-Mouse IgG, Fcy Subclass 1 specific (Jackson Immuno, USA) 
• FITC, Donkey anti-Goat, IgG +  AlexaFluor 647, Donkey anti-Mouse, 
IgG (Jackson Immuno, USA) 
• FITC, Donkey anti-Rabbit, IgG + AlexaFluor 647, Donkey anti-Mouse, 
IgG (Jackson Immuno, USA) 
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• FITC, Donkey anti-Mouse, IgG + AlexaFluor 647, Donkey anti-Rabbit, 
IgG (Jackson Immuno, USA) 
METHODS 
Section were incubated in Antigen Retrieval solution (10mM Sodium 
Citrate pH 6.0, 10mM Tris-HCl pH 6.0) for 2 minutes at >85°C and then 
washed two times in PBS 1x. Later, slices were permeabilized for 30 minutes 
in 0.3% H2O2 and then washed again two times in PBS 1x. Slices were 
blocked for 1 hour on 5% normal donkey serum (NDS) and 0.1% PBSTx at 
RT. After other washes, slices were incubated overnight at 4°C with the 
primary antibody with 1% NDS and 0.1% PBSTx. The day after slices were 
washed two times in 0.1% PBSTx and once in PBS 1x and then incubated 
with the secondary antibody for 2 hours at room temperature. After three 
other washes slices were finally mounted onto gel coated slides and covered 
(FluorSave mounting medium, Calbiochem, USA). Once that slides were 
dried, they were examined under confocal microscope at 5x and 20x 
magnitude in the hippocampal area. 
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4. RESULTS 
 
Neuroprotective effects by deletion of CD36 receptor were evaluated in 
a murine model of unilateral MCAo. Mice were divided in four experimental 
groups: one group wild type (WT), and one group knockout for CD36 that 
received MCAo (CD36-/-); and two groups of sham animals that received the 
same treatment but without the occlusion by the intraluminal filament (sham 
WT and sham CD36-/-). 
Initially we monitored the recovery from the injury induced. In order to 
do this, we recorded weight and temperature variations until the end of the 
experiment. As shown in figure 41 temperature is significantly different 
between WT group and sham WT in different days during the experiment 
underling the difficulty to recover for lesioned mice.  
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Figure 41. Temperature variations during 6 weeks. Temperature was taken once a week 
after the surgery for six week. Values are expressed as mean±SEM (n=10) of the temperature 
(°C). (4 day: p<0.01, WT vs sham WT; 14 day: p<0.01, WT vs sham WT; 21 day: p<0.05, WT 
vs sham WT; 42 day: p<0.0001, WT vs sham WT; p<0.05, CD36-/- vs sham CD36-/-; ANOVA, 
post-hoc test Bonferroni).  
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More interestingly it is not possible to see the same difference in CD36 
knockout mice; this condition shows a faster recovery in CD36-/- mice than in 
WT group. On the other hand, the variation in the body weight of sham 
groups (considered as the percentage of the difference in the body weight 
between the day of the test and the day before the surgery) is significantly 
different with respect to lesioned mice (Fig. 42). 
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Figure 42. Weight loss percentage variation during 6 weeks. Mice were weighted once a 
week after the surgery for six week. Values are expressed as mean±SEM (n=10) of the weight 
(g) compared to the weight of the same animals the day before the surgery. (4 day: p<0.05, 
WT vs sham WT, 7 day: p<0,0001, WT vs sham WT; p<0,001, CD36-/- vs sham CD36-/-, 14 
day: p<0,001, WT vs sham WT; p<0,001, CD36-/- vs sham CD36-/-, 21 day: p<0,001, WT vs 
sham WT; p<0,01, CD36-/- vs sham CD36-/-, 28 day: p<0,001, WT vs sham WT; p<0,05, CD36-
/-
 vs sham CD36-/-, 35 day: p<0,001, WT vs sham WT; p<0,001, CD36-/- vs sham CD36-/- 42 
day: p<0,0001, WT vs sham WT, p<0,01; CD36-/- vs sham CD36-/-; ANOVA, post-hoc test 
Bonferroni). 
Subsequently, we investigated the extension of the lesion using the 
modified Bederson test and the Corner test. The first test permitted to define 
the neurological assessment using a score presentation enclosed by 0 and 
4. As we expected, figure 43 shows an important difference within sham 
groups and lesioned mice during the time course of our experiment, this 
result confirmed the validity of our MCAo model. 
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Figure 43. Variations in Bederson test evaluation during 6 weeks. Mice were tested and 
scored with a value between 0 and 4 to exprime motorial functions’ compromisation. Data are 
expressed as mean ± SEM (n=10) of the value attribued to each animal. 
The Corner test permitted to evaluate sensory motor integration and the 
extension of the lesion (Fig. 44).  
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Figure 44. Corner test evaluation during 6 weeks. Mice were tested and scored once a 
week. Values are expressed as mean±SEM (n=10) of the percentual number of rotation in both 
side in 10 minutes. (4 day: p<0.0001, WT vs sham WT; p<0.0001, CD36-/- vs sham CD36-/-; 7 
day: p<0.001, WT vs sham WT; p<0.05, CD36-/- vs sham CD36-/-; 14 day: p<0.05, WT vs 
sham WT; p<0.01, CD36-/- vs sham CD36-/-; 21 day: p<0.05, WT vs sham WT; 28 day: p<0.05, 
WT vs sham WT; 35 day: p<0.0001, WT vs sham WT; p<0.001, CD36-/- vs sham CD36-/-; 42 
day: p<0.01, WT vs sham WT; ANOVA, post-hoc test Bonferroni). 
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Lesioned mice are not able to percept the board with the right vibrissae 
and consequently those rotations may be predominantly to the lesioned 
hemisphere (right). We demonstrated a consistent difference between 
lesioned mice and sham groups throughout six weeks, especially for the WT 
group compared to the equivalent sham group. 
In addiction we evaluated muscular strength with the Hanging wire test 
to define differences in our experimental groups. Our results highlight a 
significant decrease of strength in WT group as compared to CD36-/- 
(p<0.001) 7 days after the surgery. On the other hand, we evidenced many 
difference between sham groups and lesioned mice but not between WT 
and CD36-/-, especially from day 28 after the surgery. Figure 45 shows 
clearly, during the entire time course, an evident decrease in the strength of 
WT mice. 
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Figure 45. Muscular strength evaluation by hanging wire test during 6 weeks. Mice were 
tested once a week. Values are expressed as mean value±SEM (n=10) of the time (s) that the 
animal spent on the wire. (7 day: p<0.001, WT vs CD36-/-; t test, Welch’s Correction; 21 day: 
p<0.05, WT vs sham WT; 28 day: p<0.001, WT vs sham WT; p<0.05, CD36-/- vs sham CD36-/-; 
35 day: p<0.05, WT vs CD36-/-; 42 day: p<0.01, WT vs sham WT; ANOVA, post-hoc test 
Bonferroni). 
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Furthermore, we considered the coordination and balance with the Pole 
test. This test permits to evaluate the first skill through the time that animals 
need to rotate on himself to result facing down on the top of the pole. The 
time required was related with the time taken from the same animal the day 
before the surgery. In this way was possible to establish that WT lesioned 
mice required much more time for the rotation than sham animals (4 days: 
p<0.001; 14 days: p<0.0001; 42 days: p<0.05, Fig. 46a). Interestingly, sham 
groups maintained the same time for the rotation, while we observed a 
progressive improvement in the task for CD36-/- lesioned mice. Balance 
involvement was studied through the time spent to descend the pole. As for 
the rotation time, we related the duration of the task with the performance of 
the same animal the day before the surgery. The figure 46b shows a 
significant difference between MCAo mice and sham groups, but nothing 
relevant among the lesioned groups. 
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Figure 46. Pole test evaluation of coordination (time to rotate, a) and balance (time to 
descend, b) during 6 weeks. Mice were tested every two weeks. Values are expressed as the 
mean value±SEM (n=10) of the relative time required to turn (a) or descend (b) the pole and the 
time spent for the same task the day before the surgery. (a: 4 days: p<0.001, WT vs sham WT; 
p<0.05, CD36-/- vs sham CD36-/-; 14 days: p<0.001, WT vs sham WT; p<0.0001, WT vs CD36-/-; 
28 days: p<0.05, CD36-/- vs sham CD36-/-; 42 days: p<0.05, WT vs sham WT. b: 14 days: 
p<0.001, WT vs sham WT; 28 days: p<0.01, WT vs sham WT; t test, Welch’s correction).  
Finally, in view to evaluate the sensitivity to perceive an unknown object 
and the ability to control faint movements, we performed Sticky tape test. 
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This test permits to study many different aspects of the motor coordination 
and their related damages. We used the time to enter in contact for the first 
time with the tape as a proof of the sensitivity in perception. As shown in 
figure 47, the time required to contact the contralateral side (controlled by 
the lesioned hemisphere) related to the ipsilateral side (controlled by the 
healthy hemisphere) is absolutely equivalent for all experimental groups 
before the surgery, but it is significantly higher in lesioned mice than in sham 
mice after the lesion induced. We observed a significant difference between 
WT mice and the respective sham group, but not between the other two 
experimental groups (7 days: p<0.01; 21 days: p<0.01; 35 days: p<0.01). 
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Figure 47. Time to contact in the sticky tape test during 6 weeks. Mice were tested every 
two weeks. Values are expressed as mean value±SEM (n=10) of the relative time that animals 
need to contact the contralateral paw and the time for the ipsilateral side. (7 days: p<0.01, WT 
vs sham WT; 21 days: p<0.01, WT vs sham WT; 35 days: p<0.01, Wt vs sham WT; p<0.05, 
CD36-/- vs sham CD36-/-; t test, Welch’s correction). 
In order to evaluate the ability to control faint movements, we estimated 
the time spent by animals to remove an unknown object from the moment of 
the first perception of it. We related the time to remove the contralateral side 
to the ipsilateral side, as shown in figure 48, before the MCAo, all mice 
showed a similar relation, comparable to one. By contrast, from the seventh 
day after the lesion, although CD36 knockout mice resulted to be impaired 
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compared to the respective sham group (7 days: p<0.01, CD36-/- vs sham 
CD36-/-; 21 days: p<0.05, CD36-/- vs sham CD36-/-; 35 days: p<0.01, CD36-/- 
vs sham CD36-/-), WT animals were much more compromised as compared 
to the respective sham animals (7 days: p<0.01, WT vs sham WT; 21 days: 
p<0.01, WT vs sham WT; 35 days: p<0.01, WT vs sham WT). More 
interestingly, throughout the experiment we observed a significant difference 
between WT lesioned mice and CD36-/- lesioned animals (7 days: p<0.05, 
WT vs CD36-/-; 21 days: p<0.01, WT vs CD36-/-; 35 days: p<0.01, WT vs 
CD36-/-).    
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Figure 48. Time to remove in sticky tape test during 6 weeks. Mice were tested every two 
weeks. Values are expressed as mean value±SEM (n=10) of the relative time that animals 
spent to remove the contralateral and the ipsilateral side. (7 days: p<0.01, WT vs sham WT; 
p<0.01, CD36-/- vs sham CD36-/-; p<0.05, WT vs CD36-/-; 21 days: p<0.01, WT vs sham WT; 
p<0.05, CD36-/- vs sham CD36-/-; p<0.01, WT vs CD36-/-; 35 days: p<0.01, WT vs sham WT; 
p<0.01, CD36-/- vs sham CD36-/-; p<0.05, WT vs CD36-/-; t test, Welch’s correction). 
The last parameter that we investigated through the sticky tape test 
was the latency to respond, as the recorded time between the time for the 
removal and the time of the first contact always by relating the contralateral 
and ipsilateral sides. In this case, we observed that WT animals needed a 
longer time than CD36-/- mice to assess the task (7days: p<0.05, WT vs 
CD36-/-; 21 days: p<0.01, WT vs CD36-/-; Fig. 49), showing a better outcome 
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of knockout mice. This parameter is extremely important because it is strictly 
related to the ability to the control of the faint movements. 
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Figure 49. Latency to remove the tape from the first time of contact in the sticky tape 
test during 6 weeks. Mice were tested every two weeks. Values are expressed as mean 
value±SEM (n=10) of the relative time spent to remove the tape after the contact in the 
contralateral and ipsilateral side. (7 days: p<0.05, WT vs sham WT; p<0.05, WT vs CD36-/-; 21 
days: p<0.01, WT vs sham WT; p<0.01, WT vs CD36-/-; 35 days: p<0.05, WT vs sham WT; 
p<0.05, CD36-/- vs sham CD36-/-; t test, Welch’s correction).  
Starting from the third week after the MCAo induction, we assessed 
cognitive behavioral tests to elucidate the possible impairment of declarative 
and non-declarative memory. For this purpose, we performed the Novel 
object recognition test. The test permits to evaluate the time spent by 
animals in the exploration of a new object. Our results did not show a better 
outcome in knockout animals as compared to WT. On the other hand, the 
time spent in the exploration of the unknown object, is higher in the sham 
groups than in the lesioned mice (Fig. 50).  
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Figure 50. Novel Object Recognition Test during 6 weeks. Mice were tested every week 
from the third week after the surgery. Values are expressed as the mean value±SEM (n=10) of 
the percentual time (%) spent in the exploration of the novel object. (28 days: p<0.05, WT vs 
CD36-/-; ANOVA; post-hoc test Bonferroni). 
As in previous cognitive test, also the Y-Maze test could be used to 
consider the involvement of non-declarative memory. The test permits to 
evaluate the time spent by mice in the exploration of a new environment. 
Our results did not show any difference among the four experimental groups 
(Fig. 51). 
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Figure 51. Y-Maze test during 6 weeks. Mice were tested once a week from the third week 
after the surgery. Values are expressed as mean value±SEM (n=10) of the percentual time (%) 
spent in the exploration of the new arm. 
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Finally, after the sacrifice, tissues were collected and we proceeded 
with immunohistofluorescence analysis of the sections collected at 
microtome. Figure 52 shows an example of hippocampal area lesioned 
(right) and contralateral (left) in WT, CD36-/- and shams groups stained with 
Neun (red) and PCNA (green). Images show neurons and neurons in 
division at 42 days after the surgery, presenting how the hemisphere 
lesioned of knockout mice has some neurons in division. 
  
CBGS28 SHAM  LEFT CBGS28 SHAM RIGHT 
  
CBGS25 WT LEFT CBGS25 WT RIGHT 
  
CBGS19 CD36-/- LEFT CBGS19 CD36-/- RIGHT 
Figure 52. PCNA+NeuN. Representative images of hippocampal area. Magnitude 20x, scale 
bar 100 µm. PCNA green by FITC anti-mouse IgG2a, NeuN red by Cy3. 
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In order to localize angiogenic process and relate it to the 
neurodegenerative process, we stained together Glut1 and PCNA in WT 
lesioned and sham mice (Fig. 53). Interestingly, we noticed that the process 
was prevalent in MCAo mice than in sham animals. Moreover, the damage 
induced by the occlusion was expanded to the hippocampal area where is 
possible to notice the angiogenic process. 
 
  
CBGS21 SHAM LEFT CBFS21 SHAM RIGHT 
  
LGGS33 WT LEFT LGGS33 WT RIGHT 
Figure 53. PCNA+Glut1. Representative images of hippocampal area. Magnitude 20x, scale 
bar 100 µm. Glut1 green by FITC anti-rabbit, PCNA red by AlexaFluor 647 anti-mouse. 
 
We also investigated inflammatory response in the long term 
development after the injury induced; at this purpose we stained Iba1 with 
GFAP to localize microglia and astrocytes (Fig. 54). Pictures illustrate that as 
in sham group responses are equivalent in any hemispheres, on the other 
hand WT show an higher microglia expression in the lesioned side, while 
CD36-/- illustrates more astrocytes activation. 
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CBGS28 SHAM LEFT CBGS28 SHAM RIGHT 
  
LGGS34 WT LEFT LGGS34 WT RIGHT 
  
CBGS22 CD36-/- LEFT CBGS22 CD36-/- RIGHT 
Figure 54. GFAP+Iba1. Representative images of hippocampal area. Magnitude 20x, scale bar 
100 µm. GFAP green by FITC anti-mouse, Iba1 red by AlexaFluor 647 anti-rabbit. 
 
Finally, we investigated the relation between neuronal migration and 
neurogenesis process in hippocampal area. In this order we stained DCX 
and PCNA, as shown in figure 55 CD36-/- mice present a higher neurons in 
division than in WT animals. 
Part II                                                                                                                     Results 
 
 
124 
  
CBGS28 SHAM LEFT CBGS28 SHAM RIGHT 
  
LGGS32 WT LEFT LGGS32 WT RIGHT 
  
CBGS22 CD36-/- LEFT CBGS22 CD36-/- RIGHT 
Figure 55. DCX+PCNA. Representative images of hippocampal area. Magnitude 20x, scale bar 
100 µm. DCX green by FITC anti-goat, PCNA red by AlexaFluor 647 anti-mouse 
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5. DISCUSSION 
 
Cerebral stroke is one of the major causes of death in industrialized 
countries (124). Vascular inflammation and oxidative stress are the main 
pathways through which stroke risk factors enforce their damaging effects on 
blood vessels. In particular, we focused our attention on the role of 
inflammation and how it may be modulated to obtain a better motor and 
cognitive outcome. 
Inflammation is a double faced mechanism, on the one hand 
determines an increased cerebral blood flow to the affected area and the 
removal of damaged tissue by phagocytic cells; on the other hand, secretory 
factors such as cytokines and chemokines may reach toxic levels, besides 
the incremented ROS production and the consequent destruction of the BBB 
(196). 
CD36 receptor is a class B scavenger receptor responsible for the 
regulation of physiological and pathological functions. The activation of 
CD36 is involved in several risk factors for stroke disease. In particular its 
activation determines an inflammatory response through the involvement of 
NFκB (209).  
Cerebral ischemia determines an important impact on motor ability and 
cognitive functions (148, 149). In this context, it is clear that this type of 
acute degeneration may be easily compared with the dysfunctions caused 
by other neurodegenerative chronic diseases. In fact several motor 
behavioral test that we used in this experiment, were previously used for PD, 
as the cognitive tests were used for AD. Keeping in mind that many 
processes underling the evolution of the pathology are strictly related with 
chronic neurodegenerative diseases, the gap between these two types of 
CNS disorders has not to be considered so wide. 
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 For this reason, we decided to investigate the potential contribute of 
CD36 receptor, as fundamental key point in the modulation of the outcome 
after stroke. Several in vivo studies have shown motor deficit in mice after 
MCAo, especially in the first days after the injury (213). We decided to 
perform a long term study (six weeks) to assess motor and cognitive task 
with the intent to underlie how the suppression of CD36 receptor may have a 
crucial role in the extension of the lesioned area after cerebral ischemia. We 
used a transgenic mouse model CD36 knockout, which has been surgically 
induced MCAo by the insertion of an intraluminal filament. From the fourth 
day after the lesion for six weeks, we performed behavioral motor skills to 
investigate coordination, balance, strength and sensitivity. Moreover from 
the third week after the surgery we also performed cognitive behavioral tests 
to evaluate the involvement of declarative and non-declarative memory. 
In first instance, our results showed that CD36 knockout mice 
demonstrated a better recovery from the surgery than WT, this confirmed 
what previously assessed by Cho et al, indicating that the suppression of 
inflammation could be a key target for the modulation of the pathology (208). 
For what that concern the extension of the lesion we used modified 
Bederson test and the corner test. In our experiment, both MCAo groups 
presented, as we expected, significant variation compared to sham groups, 
even if the difference observed in WT mice is slightly more evident. 
After that, we evaluated the muscular strength by the hanging wire test, 
and we found that WT animals, after the lesion induced, had a significant 
loss of strength, and the different is much more important in the first 
evaluation after the damage, as shown by Wang et al in the early stages 
after the stroke induced (214). 
Furthermore, we considered the balance and the coordination of 
animals by pole test. Interestingly, we observed an important decrease in 
coordination ability in WT lesion mice than in CD36-/- damaged animals but 
the variation in balance capacity were observable only through WT groups. 
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Our results are supported by Linden et al that showed a consistent 
impairment in balance and coordination in MCAo mice compared with sham 
animals in a short term experiment than ours (215). The performance of 
CD36(-/-) may be indicative for a better motor outcome in transgenic mice 
after cerebral stroke induction.  
Finally, the sticky tape test has permitted to establish the ability to 
control faint movements and the sensitivity to perceive an unknown object. 
Our results showed through the time to contact the first time the tape that 
both lesioned groups presented a longer time than sham groups, especially 
WT animals during the entire time course. The ability to control faint 
movements was particularly compromised in WT animals than in transgenic 
mice, but we would like to focalize on the significant difference that we 
observed between lesioned groups. The last consideration on the sticky tape 
test is about the latency time between the first contact with the tape and its 
removal, this data is useful to confirm what we earlier observed with the time 
to remove the tape. Thus, the CD36 suppression results in less motor 
impairment in our murine model of cerebral ischemia.  
Unfortunately, the cognitive observations didn’t show what we 
expected. Either novel object recognition test or Y-maze test showed any 
consistent differences among our four experimental groups. Our results are 
confirmed by Bouët et al, they previously observed that ischemia did not 
alter spatial learning abilities, as we found in Y-maze test (180). 
Furthermore, Blasi et al in a subcortical white matter stroke experiment did 
not observe any differences in Y-maze test but, by contrast, they showed a 
significant impairment in novel object recognition test (216). In this contest 
we have to consider some experimental aspects. In our experimental time 
course, we decided to perform cognitive evaluation from the third week after 
surgery every week. This decision may have determined that, if animals 
didn’t have an extended lesion, probably they could remember from one trial 
to the other what they already performed previously. In this case it may be 
not possible to show a consistent difference between lesioned mice and 
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sham groups because probably not completely lesioned animals could 
remember the object (or the environment) and then the result of the test 
would be compromised. The last consideration is about the animals’ age, 
indeed, a human experiment on cognitive deficits after a stroke event, 
showed that only the 20.4-34.8% of the young patients compared to 77% of 
elderly stroke survivors presented cognitive features. Thus, 8 weeks of age 
for mice may be not enough to show a significant cognitive impairment. This 
may due partially to the fact that younger stroke survivors have a better 
collateral blood supply (217). 
After the behavioral analysis mice were sacrificed and we proceeded 
with immunofluorescent investigation. Pictures presented are representative 
examples of our work. They show that the tissue is better conserved in 
CD36 knockout mice than in WT animals. WT animals displayed more 
lesions and, as we expected, in the lesioned hemisphere, the angiogenetic 
process is more extensive in the damaged area. The better conservation of 
tissue in CD36(-/-) mice may be explained by  the study of Cho et al which 
showed the anti-angiogenic role of CD36, that support also the better 
behavior outcome observed in knockout mice (208).  The neurogenesis 
process is not only more representative in CD36-/- mice, but also after the 
lesion in both groups. The inflammation response by microglia and 
astrocytes showed a higher activation after the MCAo, and the activation is 
still present in CD36-/- animals. Probably the activation of a mild inflammatory 
response would be important to explain the raised neurogenic process; 
indeed Chen et al explained that the activation of microglia following a brain 
injury may actively enhance neurogenesis by producing insulin-like growth 
factor-1 (218). Our considerations about the importance of CD36 receptor in 
the outcome after stroke are confirmed by Kim et al, who showed in an acute 
ischemia induced study, the protective effects of targeting the receptor of our 
interest (219). Besides these considerations, our study needs further 
investigations.  
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In conclusion, we can affirm that the knockout of CD36 receptor could 
have a protective role in neuroinflammation after a stroke event as shown by 
motor impairments considerations. From the moment that many mechanisms 
that underlie ROS production and spreading brain inflammation are common 
in both acute and chronic neurodegenerative diseases, it will be interesting 
to investigate the role of CD36 also in other neurodegenerative pathologies 
and how it is possible to modulate the receptor in order to obtain a slower 
progression of the brain lesion. 
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Conclusions 
 
Different neurodegenerative diseases have shown to share similar 
dysfunctional features.  Although if the epidemiology of the most of them is 
not certain yet, especially for neurodegenerative chronic diseases, oxidative 
stress, inflammation, excitotoxicity and neuronal loss are extremely involved 
in the evolution and progression of the pathology, both in chronic and acute 
conditions. The brain is the organ more exposed to oxidative stress because 
of the high rate of oxygen consumption related to the detoxification 
mechanism. For this reason, any variation in this balance could play a 
dramatic role in the evolution of a brain damage (42).   Inflammatory 
response and oxidative stress are closely related to each other by a double 
chain; increasing oxidative condition raises the inflammatory response that, 
in turn, causes oxidative stress. The complexity of the brain structure and 
functions still not permit to describe clearly how these pathologies could 
evolve, but it is possible to observe a superposition among them. For 
example many motor tests, already used in the study of PD, have shown a 
good outcome in the study of motor impairment after an ischemic cerebral 
event. This is possible because the brain structures involved in these two 
diseases are comparable. On the other hand, many patients present an AD 
condition after a history of cerebral ischemia due to an overexpression of β-
amyloid plaques (12). All these considerations allow us to affirm that there is 
a tight junction between chronic and acute neurodegenerative diseases, 
although if the causes and the epidemiology are often distant and completely 
different.  
In this context the concept of neuroprotection, as an intervention to 
slow down or arrest the evolution of pathology, may have a powerful role. 
Any intervention able to interfere with the inflammatory response and 
oxidative stress could play a crucial role in the progressive impairment of the 
quality life of patients. Neuroprotection could work in synergy with the 
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endogenous systems, quenching ROS formation or restoring the antioxidant 
GSH system and its related enzymes, as GR and GST; and not less 
important slowing down the apoptotic neuronal death. Thus, the present 
study we used a murine model of PD treated with a powerful antioxidant 
molecule, 6-MSITC. As already highlighted, inflammation is a fundamental 
characteristic in the evolution of neurodegenerative chronic and acute 
diseases; in fact various studies have shown how NSAIDs could exert 
neuroprotective effects in PD animal models (21, 38). For this reason, the 
modulation of this response is also a key point in the neuroprotection 
strategy. In the second study a transgenic mouse model knockout for CD36 
receptor has been utilized to investigate the involvement of the inflammation 
in a long term study of MCAo. The results show that the suppression of this 
receptor determines a better outcome in mice after the induced damage; 
therefore, we think that a good neuroprotective therapy could be useful in a 
better outcome in ischemic patients.  
In this work it has been shown how is possible to modulate a 
neuroprotective response by a powerful antioxidant molecule, 6-MSITC, in a 
preclinical murine model of PD and the modulation of inflammatory response 
by the suppression of CD36 receptor in a preclinical model of MCAo. 
Because of the common mechanisms involved in the spreading of 
neurodegenerative pathologies, chronic and acute neurodegenerative 
diseases are not so far each other as they seem to be. It will be interesting 
to investigate the neuroprotective activity of antioxidant molecules in 
cerebral ischemia, especially the possible action on the penumbra, the area 
where neurons appear damaged, but not irreversible compromised. On the 
other hand the CD36 receptor has shown interesting property in the control 
and evolution of the inflammatory response, and it would be interesting to 
investigate its role in chronic diseases. 
  In conclusion, results in this study allow underlying the connection 
among pathologies that involved CNS, and the importance of a 
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neuroprotective strategy able to restore neurons activity where current drugs 
therapies have shown palliative but not healing abilities.  
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